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i
Abstract
De novo peptide sequencing from MS/MS spectra has become of primary importance in proteomics. It
provides essential information for studies of protein structure and function. With the availability of various
MS/MS spectra, a lot of computational methods have been developed to infer peptide sequences from them.
However, current de novo peptide sequencing methods still have limitations. Some major ones include a
lack of suitable models reecting MS/MS spectra, limited information extracted from MS/MS spectra, and
the inecient use of multiple spectra. This thesis addresses some of the limitations with a series of novel
computational methods designed for various MS/MS spectra and their combinations.
The main content of the thesis starts with a comprehensive review of recent developments in de novo
peptide sequencing methods, followed by two novel methods for single spectrum sequencing problems, and
then presents two paired spectra sequencing methods. The rst chapter introduces relevant background
information, objectives of the study, and the structure of the thesis. After that, a comprehensive review of
de novo peptide sequencing methods is given. It summarizes recent developments of computational methods
for various experimental spectra, compares and analyzes their advantages and disadvantages, and points
out some future research directions. Having these potential research directions, the thesis next presents
two novel methods designed for higher-energy collisional dissociation (HCD) spectra and electron capture
dissociation (ECD) (or electron transfer dissociation (ETD)) spectra, respectively. These methods apply new
spectrum graph models with multiple types of edges, integrate amino acid combination (AAC) information
and peptide tags, and consider spectrum-specic information to suit dierent spectra. After that, multiple
spectra sequencing problem is studied. A framework for de novo peptide sequencing of multiple spectra
is given with applications to two dierent spectra pairs. One pair is spectrally complementary to each
other, and the other is similar spectra with property dierences. These methods include eective spectra
merging criteria and parent mass correction steps, and modify the previously proposed graph models to t
the merged spectra. Experiments on several experimental MS/MS spectra datasets and datasets pairs show
the advantages of the proposed methods in terms of peptide sequencing accuracy. Finally, conclusions and
future work directions are given at the end of the thesis.
To summarize the work in the thesis, a series of novel computational methods for de novo peptide
sequencing are proposed. These methods target dierent types of MS/MS spectra and their combinations.
Experiential results show the proposed methods are either better than competing methods that already exist,
or ll gaps in the suite of currently available methods .
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Chapter 1
Introduction
1.1 Background
Proteins are crucial entities of biological organisms. One important step to understand proteins is to know
their sequences. The following are three main reasons of studying protein sequences. First, since a protein's
sequence is unique, to at least some degree it helps distinguish proteins. Second, the sequence is the primary
structure of a protein, so it is the basis of understanding the higher level structure and function of the
protein. Finally, since most basic cellular processes are carried out by multiple proteins through molecular
interactions, it helps the study of protein-protein interactions and molecular biology of proteins [3].
In the study of protein sequences, a typical strategy is to break them into smaller parts, which are peptides,
and infer peptide sequences rst instead. Therefore, peptide sequencing has become a prime concern in current
proteomics [4].
Peptides are organic compounds consisting of two or more amino acids. Amino acids are molecules
containing an amino group, a carboxyl group and a side chain that varies between dierent amino acids. The
side chain is represented by R in Figure 1.1. It is the residue that distinguishes one amino acid from another.
One nitrogen atom and two hydrogen atoms comprise the amino group ( NH2), and one carbon atom, one
oxygen atom and one hydroxyl (OH) constitute the carboxyl group ( COOH). The general structure of an
amino acid is shown in Figure 1.1.
Figure 1.1: The general structure of an amino acid.
Two amino acids connect to each other when one's carboxyl group reacts with the other's amino group,
creating a peptide bond ( C(= O)NH ) and losing a molecule of water (H2O ). The reaction of two amino
acids is illustrated in Figure 1.2, where R and R0 represent two side chains (residues). The elements in the
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blue circle represent the water (H2O) to be released, and the elements in the red circle represent the resulting
peptide bond ( C(= O)NH ).
There are twenty standard amino acids in nature composing peptides and proteins. Each of them has
been assigned an one-letter code for simplicity in use.
Figure 1.2: The reaction of two amino acids forming a peptide
Nowadays, tandem mass spectrometry (MS/MS) has emerged as a major technology for peptide sequenc-
ing because of the high throughput data it can generate in a short amount of time and its exceptional
sensitivity [5{7]. A typical procedure of the MS/MS can be summarized as follows. Protein mixtures are
rst digested into suitably sized peptides for mass spectrometric analysis using site-specic proteases (usu-
ally trypsin). Then the peptides are ionized via an ionization process. After that, some selected ions are
further fragmented into fragment ions, and the output of MS/MS is a diagram called a tandem mass spec-
trum (MS/MS spectrum) [8{11]. An MS/MS spectrum usually contains two kinds of information organized
together as ordered pairs, the mass-to-charge ratio (m=z) values of fragment ions and the corresponding
intensities. Therefore, MS/MS works like a charged sieve; we can only get a series of charged fragments from
it [12]. Large molecules are broken into small pieces, and the problem of peptide sequencing is to nd out
the whole sequence of the peptide from these fragments [13].
Dierent kinds of fragment ions occur during MS/MS depending on the cleavage positions on peptide
backbones, and the most frequently observed six kinds of them are named a-ions, b-ions, c-ions, x-ions, y-
ions, and z-ions. With various fragmentation techniques used in MS/MS, dierent kinds of output spectra
have diering dominant fragment ions and other unique properties. The commonly used ones include collision-
induced dissociation (CID), higher-energy collisional dissociation (HCD), electron capture dissociation (ECD)
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and electron transfer dissociation (ETD). CID was the most commonly used technique when people started to
use MS/MS for peptide sequencing, while the other three are newly developed techniques that are presently
widely used. In this thesis, dierent kinds of MS/MS spectra are investigated and a series of computational
peptide sequencing methods for various MS/MS spectra are developed.
1.2 Motivation and Objectives
When solving mass spectrometry-based peptide sequencing problems, database searching, peptide tagging and
de novo sequencing are the most popular methods [14{18]. In database searching, theoretical spectra [19]
are computed from an existing protein database and peptides are identied by matching the theoretical
spectra to experimental spectra [20]. Peptide tagging [21, 22] produces partial sequences, often called tags,
from an MS/MS spectrum, and then this information is usually combined with database searching or de
novo sequencing to reduce the scale of computation. When combined with database searching, tags can be
used as a lter to select candidate peptides that contain those partial sequences; when combined with de
novo sequencing, a tag can be used as a starting point that is extended to get full candidate sequences.
The last method, de novo sequencing, usually automatically interprets spectra using the masses of amino
acids [1,23{26]. Because of its independence of databases, it can identify new proteins, proteins resulting from
mutations, proteins with unexpected modications and so on. Therefore, it is worth studying and developing
the de novo sequencing methods.
Current de novo sequencing methods mainly have three limitations. First, the models constructed usually
do not perfectly reect MS/MS spectra. The second limitation is that less information is extracted than could
be from an MS/MS spectrum. Lastly, early developed peptide identication methods only use one MS/MS
spectrum, usually the CID spectrum, to infer the peptide sequence. The use of alternative MS/MS spectra and
multiple spectra of the same peptide have the potential to signicantly increase the accuracy and practicality
of de novo sequencing. Facing these challenges and potentials, this study has the following objectives.
Objective 1: Review literature of currently developed de novo peptide sequencing methods and analyze
their advantages and disadvantages.
Objective 2: Design a new model containing more useful information from MS/MS spectra for de novo
peptide sequencing.
Objective 3: Design eective algorithms for de novo peptide sequencing using alternative spectra other
than the traditional CID spectra.
Objective 4: Develop a framework of de novo peptide sequencing using multiple spectra based on
graph-theoretic models.
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1.3 Organization of the Thesis
This is a manuscript-style thesis. It is presented as a series of manuscripts for which I am the rst author
and primary investigator. These manuscripts were either published or submitted to specic journals during
my Ph.D. study. The order of the manuscripts is accordant with the objectives. At the beginning of each
chapter, detailed publication or submission information is given, followed by a brief introduction describing
the connection of the manuscript to the context of the thesis. The format of all manuscripts has been adjusted
to achieve consistency of format and style. All references of the publications have been unied and there is
only one bibliography at the end of all chapters for the entire thesis.
The remainder of the thesis is organized as follows: Chapter 2 presents a comprehensive review of de
novo peptide sequencing methods. It summarizes recent developments of computational methods for various
types of typical experimental data, compares and analyzes their advantages and disadvantages, and points
out some future research directions. Chapter 3 presents a new method named NovoHCD for de novo peptide
sequencing. It applies a spectrum graph model with multiple types of edges, and integrates amino acid
combination (AAC) information and peptide tags. This method has been applied to higher-energy collisional
dissociation (HCD) spectra. It is compared to other similar methods on several experimental datasets to
show its sequencing performance. Chapter 4 presents a de novo sequencing method for electron capture
dissociation (ECD) and electron transfer dissociation (ETD) spectra named NovoExD. NovoExD modies
the model in NovoHCD to t ECD/ETD spectra, and considers multiple peptide tags and fragment ion
charge information. Its performance is then compared to another similar method. Chapter 5 presents a
framework for multiple spectra sequencing and applies it to paired CID (or HCD) and ECD (or ETD)
spectra. These spectra pairs have dierent dominant fragment ions and are complementary to each other.
The performance of the framework is compared to another similar method named pNovo+. The results show
that the proposed framework outperforms pNovo+ on several experimental datasets. Chapter 6 presents a de
novo peptide sequencing method for CID and HCD spectra pairs. These spectra pairs have similar dominant
ions but are accompanied by other ion types with dierent properties. Less attention has been paid in
the literature to these spectra pairs. The proposed method includes a merging criteria of CID and HCD
spectra and a parent mass correction step, and modies a previously proposed algorithm for sequencing the
merged spectra. The proposed method and other two methods designed for single spectrum (HCD and CID)
sequencing are evaluated for performance. Finally, Chapter 7 concludes the thesis and gives possible future
directions for this study. A full list of the publications produced during my Ph.D. studies is in Appendix A,
and the copyright permissions of the published manuscripts included in this thesis are in Appendix B.
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Chapter 2
Recent developments in computational methods for
de novo peptide sequencing via tandem mass spectrom-
etry (MS/MS)
Prepared as: Yan Yan, Anthony J. Kusalik and Fang-Xiang Wu. \Recent developments in computational
methods for de novo peptide sequencing via tandem mass spectrometry (MS/MS)," Protein & Peptide
Letters, accepted, August 2015.
The focus of the study in this thesis is MS/MS based de novo peptide sequencing methods. Before devel-
oping new computational methods for dierent kinds of MS/MS spectra, a comprehensive review of current
de novo peptide sequencing methods is needed. CID was the most commonly used fragmentation technique
when researchers started to apply de novo peptide sequencing methods to MS/MS spectra. Recently, with
developments of fragmentation techniques, alternative MS/MS spectra are available. Among them, the most
widely used ones are HCD, ECD, and ETD spectra. New de novo sequencing methods designed for these
spectra have become available in recent years.
This chapter gives a review of recent developments of computational methods designed for various MS/MS
spectra, especially methods for new, alternative spectra. With the availability of multiple types of spectra,
methods designed for the use of spectra combinations have been developed, and they are reviewed in this
chapter as well. This chapter summarizes dierent peptide sequencing methods available currently, compares
and analyzes advantages and disadvantages of these methods, and points out potential future research direc-
tions. The review in this chapter provides a foundation for the study conducted in this thesis on development
of new computational methods for de novo peptide sequencing.
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Abstract
Tandem mass spectrometry (MS/MS) has emerged as a major technology for peptide sequencing. Typically,
there are three kinds of methods for the peptide sequencing: database searching, peptide tagging, and de novo
sequencing. De novo sequencing has drawn increasing attention because of its independence from existing
protein databases and potential for identifying new proteins, proteins resulting from mutations, proteins
with unexpected modications and so on. Recently, with the improvements in the accuracy of MS/MS
and development of alternative fragmentation modes of MS/MS, many new de novo sequencing methods
have been formulated. This paper reviews these recently developed sequencing methods including those for
alternative MS/MS spectra. The paper rst introduces background knowledge on peptide sequencing and
mass spectrometry, and then reviews de novo peptide sequencing methods for traditional CID spectra. After
that, it focuses on the recent development of de novo peptide sequencing methods for alternative MS/MS
spectra. In addition, methods using multiple spectra from the same peptide are surveyed. Finally, conclusions
and some directions of future work are discussed.
2.1 Introduction
Peptide identication has become an important topic in current proteomics studies [27, 28]. Tandem mass
spectrometry (MS/MS) has emerged as a major technology for peptide identication [3, 5, 6, 12]. Figure 2.1
shows a typical MS/MS experiment owchart. In a typical MS/MS experiment, protein mixtures are rst
digested into suitably-sized peptides for analysis using site-specic proteases (usually trypsin). Then the
peptides are ionized via an ionization process. The two most commonly used ionization sources are Matrix-
Assisted Laser Desorption Ionization (MALDI) and Electrospray Ionization (ESI). More information about
dierent ionization sources can be found in [2]. Peptide ions are then go through a mass analyzer and their
mass-to-charge ratio (m=z) values and the corresponding intensities are measured. The generated data are
called MS spectra. After that, some selected peptides (also called precursor ions) are further fragmented into
fragment ions, and their tandem mass spectra (MS/MS spectra) are collected [8{11]. In this fragmentation
process, dierent techniques may be applied and result in various kinds of MS/MS spectra. MS/MS spectra
usually consist of two kinds of information, the mass-to-charge ratio (m=z) values of fragment ions and the
corresponding intensities.
In MS/MS, parent peptide ions are fragmented into various kinds of fragment ions, mainly along the
peptide backbone. The spine of a peptide contains three types of bonds (C C, C N , and N  C), and any
of which may be broken in MS/MS. There are 6 types of ions that commonly occur, named a-ions, b-ions,
c-ions, x-ions, y-ions, and z-ions according to their cleavage positions [29]. These ions can be in single or
multiple charge states. Notations further indicate the positions at which the fragmentation of the peptide
occurs. Figure 2.2 shows dierent cleavage sites and resultant ion types in detail. For example, in the cleavage
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Figure 2.1: Flowchart of a typical MS/MS experiment
sites between residues R1 and R2, breaking the C C bond results in two complementary ions, an a1-ion and
an x3-ion; breakage of the C N bond results in two complementary ions, a b1-ion and a y3-ion; and breaking
the N   C bond results in two complementary ions, a c1-ion and a z3-ion. In addition, the complementary
ion relationships in Equations (1)-(3) hold for the six types of ions introduced above.
ai + xN i = mp + 2mH ; (2.1)
bi + yN i = mp + 2mH ; (2.2)
ci + zN i = mp + 2mH ; (2.3)
where mp is the mass of parent peptide P , N is peptide length, and i 2 f1; 2; : : : ; Ng.
Dierent fragmentation techniques in MS/MS yield diering dominant types of fragment ions. Collision-
induced dissociation (CID) and higher-energy collisional dissociation (HCD) yield b-ions and y-ions as domi-
nating ions [30]. Electron capture dissociation (ECD) and electron transfer dissociation (ETD) preferentially
produce variants of c-ions and z-ions, and occasionally a-ions [31{33]. In addition, all the fragment ions
usually lose some small molecules such as H2O and NH3 during fragmentation [26,34].
CID was the most commonly used fragmentation technique during the early development of peptide
sequencing methods [14]. The principle of CID is shown in Figure 2.4. Selected precursor ions with positive
charge values go into the collision cell that contains an inert collision gas, and fragment into product ions
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Figure 2.2: Dierent types of ions resulting from tandem mass spectrometry [1]
Figure 2.3: Structure of an immonium ion with residue R
and/or neutral losses. More information about the principles of dierent fragmentation techniques can be
found in [2]. With the development of new techniques and instruments in recent years, alternative MS/MS
spectra with new features have appeared [35]. HCD has similar dominating ions to CID but with more
abundant ions in the low mass region (typically  200Da). Specically, there are special types of ions shown
on HCD spectra, the most informative ones being immonium ions (IMs) [36]. Figure 2.3 shows the structure
of the IM. Other useful ions include b1-ions, y1-ions, and a2=b2-ion pairs.
ECD and ETD both produce variants of c-ions and z-ions, and the fragmentation process of these ions
is shown in Figure 2.5. An ion with a dot \ means a radical fragment ion, which is a free radical species
carrying a charge. ETD [37] is a modication of the ECD technique [38] which was designed for dissociation
of multiply protonated peptide ions in MS/MS. In this study, we use ExD to represent ECD and ETD spectra
as a whole. ExD produces high quality MS/MS spectra for multi-charged peptides and has no strong cleavage
preferences. It utilizes a lower energy pathway than CID and HCD, thus preserving labile post-translational
modications (PTMs) [39{41]. All these features yield spectra containing useful information, and thus they
have the potential to give satisfying peptide sequencing performance.
The goal of peptide identication is to infer the peptide sequence from an experimental spectrum. There
are three main kinds of methods currently used for peptide sequencing: database searching, peptide tagging
and de novo sequencing [42{45].
In database searching, theoretical spectra are computed from an existing protein database and peptides are
identied by matching the theoretical spectra to experimental spectra. Dierent scoring schemes are employed
to evaluate the matches [46]. The success of database searching thus relies on proper scoring functions [47] and
the quality and extent of the existing databases. A major disadvantage of database searching is that it cannot
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Figure 2.4: The principle of CID [2]
identify new or unknown peptides that are not included in the reference database. Peptide tagging [21, 22]
usually produces partial sequences, often called tags, from an MS/MS spectrum, and then uses these tags
to search against a protein database or to help with de novo sequencing. Since the method still searches in
a known database, it cannot identify new or unknown peptides. The advantage of using tags is that it can
dramatically reduce the search space and time needed in de novo peptide sequencing. De novo sequencing
automatically interprets spectra using the masses of amino acids. It can identify new proteins, proteins
resulting from mutations, proteins with unexpected modications and so on. With the recent development
of high mass-accuracy MS/MS and alternative fragmentation techniques, de novo sequencing has shown
promising developments [48].
In this paper, we review recent developments in de novo peptide sequencing methods including some
new methods using various types of spectra. The remainder of this review is organized as follows. Section
2 focuses on the peptide sequencing methods using the traditional CID spectra. Sections 3 summarizes
some successful de novo peptide sequencing methods using alternative data such as HCD and ExD spectra.
Section 4 introduces the multiple spectra sequencing problem and some recent solutions to it. Finally section
5 concludes the review and gives possible directions of future work.
2.2 Development of de novo peptide sequencing with the use of
CID spectra
When researchers rst started to apply de novo peptide sequencing methods to MS/MS data, CID spectra
were commonly used. De novo sequencing started with straightforward methods like exhaustive listing and
manual interpretation using unique features from CID spectra, and moved to rened and comprehensive
methods like those using graph-theoretic models [49].
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Figure 2.5: Fragmentation process leading to c- and z- type of ions in ExD
2.2.1 Early developments
Exhaustive methods involve listing all possible candidate peptide sequences that can result from a parent
peptide mass in an MS/MS spectrum [50], and comparing them with an experimental spectrum to nd the best
match that has the highest possibility to generate such experimental spectrum. Typically, a suitably designed
scoring scheme is involved to measure the similarity between the experimental spectrum and the theoretical
spectrum of a candidate peptide. One computational diculty with this approach is the exponential growth in
the number of candidate sequences with increasing parent mass. Another challenge is the eect of inaccurate
parent mass determination by the rst stage of MS/MS, which leads to incorrect candidate sequences. Using
these candidate sequences, results are poor even if the scoring scheme is ne. Manual interpretation usually
employs graphical display of the MS/MS spectra, and relies on a human expert's visual skill to generate
reliable results [51]. In this method, fragment ions that dier by the mass of one amino acid residue are
highlighted by connected lines, thus allowing the visualization of ion series of the same type. This method
may work well on simple spectra or spectra generated by short peptides. However, it requires a lot of human
expertise and time.
The manual interpretation approach may seem quite simple and straightforward. Fortunately, there are
ideas that can be used to enhance this approach to de novo peptide sequencing. For example, exponential
growth in the number of candidate sequences limits the exhaustive listing for large peptides. For a peptide
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with large mass value, it is quite time-consuming to get the comparison results for every possible candidate
sequence with the experimental spectrum. But careful choice when listing partial peptide sequences can help
with the sequencing of specic regions of a peptide. With the increased performance of computer hardware,
this composition-based strategy has been applied in several recently proposed methods [52]. In addition,
manual interpretation helps with nding new features in the experimental spectra, and provides ideas and
prototypes for many methods based on the more recently developed graph-theoretic models. Fortunately, it is
still quite worthwhile looking back and nding new ideas inspired by these initial approaches when designing
new de novo sequencing methods.
2.2.2 Graph-theoretic methods
In de novo sequencing, graph-theoretic methods have proven to be quite successful and hence such algorithms
have been widely used. In these methods, a tandem mass spectrum is typically represented as a graph called
a spectrum graph. Each fragment ion is represented as a vertex and two vertices having the mass dierence
equal to one amino acid mass are connected by an edge [26,49,52].
The graph theoretical approach to de novo peptide sequencing was rst proposed in the 1990's [53{55].
The main idea is to use a graph to represent dierent partial peptide masses and their relationships as
interpreted from an MS/MS spectrum, and then to nd suitable paths in the graph which indicate the likely
peptide sequences that gave rise to the spectrum.
The Sherenga algorithm was proposed in 1999 [56] based on such a graph model. This method rst
identies ion types in MS/MS data and then constructs the graph. This step helps with limiting the size of
the graph. A merging approach is then applied using a greedy algorithm that determines which of the vertices
in the spectrum graph can be merged into one vertex. The peptide sequencing problem is then transformed
into a longest path-nding problem in a directed acyclic graph (DAG). Another useful strategy applied in the
algorithm is a parent mass correction scheme since the accuracy of the parent mass is extremely important in
de novo sequencing. A problem with this algorithm is that the best path might not correspond to a realistic
solution because it may use multiple vertices associated with the same experimental spectral peak, which
may be due to incorrect merging.
In order to solve some of the problems in the Sherenga algorithm, Chen et al. [57] proposed a dynamic
programming approach to nd the longest antisymmetric path in a spectrum graph. They introduced an NC-
spectrum graph (NC denotes N -terminal and C-terminal, respectively) for a given tandem mass spectrum,
which is constructed by assuming each peak in the spectrum is either a b-ion and a y-ion. Since each peak
generates two vertices in the spectrum graph, the total number of vertices 2k + 2, where k is the number of
peaks in the spectrum. A dynamic programming algorithm is then applied to nd longest paths from the
graph. This idea was later developed into the de novo sequencing software named MSNovo [58].
In addition, some researchers applied other mathematical matrices to extract useful information from
MS/MS spectra. One successful algorithm named PepNovo [59] uses a probabilistic network reecting the
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chemical and physical rules of the peptide fragmentation, and builds a spectrum graph to estimate the
peptide sequence. This method performed well in de novo peptide sequencing, but is highly dependent on
the training data used to generate the major parameters in the model, such as the fragmentation types and
their probabilities. Thus, the accuracy of results varied with dierent MS/MS data [60].
2.2.3 Other methods
When solving the de novo peptide sequencing problem, some researchers develop their methods based on
graph theoretical models, while others solve the problem in wholly dierent ways. One successful approach
in the latter category uses a hidden Markov model (HMM), which is a statistical model describing sequential
data with hidden information. The model ranks the likelihood between observed spectra and a given peptide
sequence. The resultant software, NovoHMM [61], is based on this model. PEAKS [62], which is also not
based on a spectrum graph model, uses dynamic programming to compute the best possible sequence among
all possible amino acid combinations. It rst applies a sophisticated dynamic programming algorithm [63] to
output the 10,000 best candidate sequences, and then uses a carefully designed scoring scheme to rank them.
Finally, it computes a condence score for each sequence output. According to recent literature, PEAKS
shows high sensitivity and good performance in peptide identication from MS/MS spectra [60]. In addition,
there are many derivatives of the original PEAKS software described [31,64] that involve other new methods
and techniques, thus making the integrated PEAKS package one of the most widely used software tools for
de novo peptide sequencing.
2.2.4 Discussion
For de novo peptide sequencing using CID spectra, dierent algorithms and software have their comparative
advantages and disadvantages, but in general, the trend is toward more eective peptide sequencing over
time. However, one needs to keep in mind that the performance of each software package may vary among
dierent spectra, instruments, techniques and experiment samples. Therefore, it is impossible to say which
one is best for peptide sequencing or which surpasses all others. Instead, researchers should carefully choose
software to t the specic peptide sequencing problem they are facing.
There are still some limitations and problems in the above methods. The rst one is that the spectrum is
typically noisy. To solve this problem, preprocessing and denoising approaches are needed [65], such as the
preprocessing in PEAKS and the work done by Sridhara et al. [66]. In addition, because the ions used to
nd paths should be of the same ion type with de novo sequencing, ion type separations are helpful in the
subsequent peptide sequencing results. Some researchers have used a graph-theoretic approach to separate
b- and y- ions in an MS/MS spectrum [67], but little further work has been done in this vein.
The second problem is missing data from MS/MS spectra. Researchers have tried to extrapolate as much
useful information as possible from the models constructed, but they are typically not able to satisfactorily
reect the actual MS/MS spectrum, and there is still a need to generate more accurate information from the
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outset [68].
There is still the potential to develop better strategies and newer models to improve sequencing perfor-
mance. For example, MSNovo [58] has integrated a new probabilistic scoring function with a mass array-based
dynamic programming algorithm to predict peptide sequences. In addition, researchers can change the def-
initions of vertices and edges in current spectrum graph models and investigates more relationships among
ions (not just the mass dierence of amino acids [69]). Since the spectrum itself contains limited information,
another possible way is to combine other approaches | for example, database searching | to estimate the
best peptide sequence from the experimental spectrum. Tag-based approaches following this strategy, such
as PARPST [70] and Vonode [69], are widely used. Instead of inferring the whole sequence, these algorithms
rst output the best peptide tag with a strict error tolerance and then use the tag to search potential peptides
in a previously specied database. These algorithms usually have advantages of shorter computation time
compared to traditional database searching methods and more accurate peptide sequencing results compared
to the traditional de novo peptide sequencing. Therefore, tag-based methods are worth studying deeper in a
deeper fashion in the future.
2.3 De novo peptide sequencing with alternative MS/MS spectra
CID was the most commonly used fragmentation technique when researchers started to use tandem mass
spectrometry for peptide sequencing. In recent years, alternative MS/MS spectra such as HCD and ExD have
appeared with the development of new techniques and instruments. Our study of these new spectra starts
with the investigation of their properties and unique features that could be used for peptide sequencing, and
then moves to the development of computational methods. In particular, we review the development of de
novo peptide sequencing using HCD and ExD spectra.
2.3.1 Methods using HCD spectra
HCD produces similar dominant ions to the traditional CID technique, but generates more ions in the low
mass region (typically  200Da). This includes ions specic to HCD spectra such as IMs (immonium ions),
which are introduced and studied in [71]. Another systematic study of the properties of HCD spectra can
be seen in [36]. From these studies, researchers have learned how to use this kind of spectra to infer peptide
sequences using de novo methods.
One successful method specically developed for HCD spectra is pNovo [72]. It applies a spectrum
graph model and combines IMs and internal fragment ion information from HCD spectra, and has achieved
superior peptide sequencing results. Since there are few algorithms available designed specically for HCD
spectra and CID spectra have similar dominant ions, the authors compared the performance of pNovo with
other algorithms designed for CID spectra. The results on various test data showed that pNovo has higher
sequencing accuracy than two previous algorithms, PEAKS [62] and PepNovo [59].
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Although de novo peptide sequencing for HCD spectra takes advantage of advanced instruments and
specically designed methods, there are still limitations to these methods, especially the insucient informa-
tion extracted from the spectrum graph model. For example, in a traditional spectrum graph like the one
used in pNovo [72], an edge is drawn between two vertices only when the mass dierence between the two
vertices is equal (or close) to one of the 20 amino acid masses. Thus if there are peaks missing in the spectrum
or the m=z values are inaccurate, it could be very dicult to nd a path through the graph representing the
correct peptide sequence. Therefore, a more suitable model with more information included is very appealing.
Since the traditional model only considers amino acid mass dierence, a graph model from MS/MS spectra
that includes multiple relationships is expected to have better performance [21].
NovoHCD [73] is such a method that uses a modied spectrum graph model with multiple types of edges
(called a multi-edge graph) for peptide sequencing. It also combines amino acid combinations (AACs) and
peptide tags to make the problem easier to solve. This method rst uses peptide tags to separate a whole
peptide sequence into three parts: prex, tag, and sux. It then builds multi-edge graph models on the prex
and sux separately for sequence interpretation, and uses AAC information to limit the number of edges
in the graph. It nally combines these three parts to generate complete sequences of candidate peptides.
Immonium ions observed particularly in HCD spectra are used in the candidate peptide ranking of NovoHCD.
From experiments on ve HCD spectra datasets, NovoHCD outperforms pNovo in terms of the accuracy [73].
2.3.2 Methods using ExD spectra
When it comes to the other new types of spectra, ExD is a popular one because of its unique properties.
ExD is a new technology that has properties dierent from CID and HCD. Recent studies of MS/MS spectra
produced by ExD have focused on the characteristics of the spectra [32, 33, 39], how various PTMs can be
identied from the spectra [40], and performance of peptide sequencing methods using such spectra [17,74].
Some of the methods that use multiple spectra for sequencing include an option to use ExD spectra alone;
for example, the one introduced in [75]. These methods typically consider only a subset of the features in ExD
spectra because their focus is not ExD spectra exclusively. Up to now, little attention has been paid to de
novo sequencing methods using solely ExD spectra. However, one recently developed method, NovoExD [17],
takes advantages of the unique features of ExD spectra to infer peptide sequences from them alone. NovoExD
uses a novel spectrum graph model, considers multiple peptide tags to separate a peptide into small mass
regions, and integrates fragment ion charge and amino acid composition (AAC) information. It combines
small regions to output complete sequences of candidate peptides. In addition, a charge determination step is
used to extract more information from highly charged ExD spectra. Experiments on three ExD datasets show
an improvement of over 20% in average full length peptide sequencing accuracy for NovoExD as compared
to a multiple spectra method with an option for ExD spectra. Given the limited number of methods for
ExD alone and the unique features of such spectra, improved methods for them would be useful and worth
studying.
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2.3.3 Discussion
The two methods NovoHCD and NovoExD achieved superior experimental results compared to other similar
approaches. They have a similar framework but with modications suitable for the new types of spectra
they utilize (HCD and ExD, respectively). The reasons for their success can be summarized as the following.
First, the framework replaces the traditional spectrum graph with a multi-edge graph, thus including more
relationships between pairs of peaks in a spectrum. Secondly, it separates whole peptide sequences into smaller
parts, and solves each sequencing subproblem separately. Lastly, AAC information is eectively incorporated
into the peptide sequencing process to limit the number of edges in the generated graph models, which also
reduces the computational cost for these methods.
In the future, exploring the unique properties of these new types of spectra, and designing innovative tech-
niques and models that utilize the novel types of information they contain, are potential research directions
that could further enhance de novo sequencing performance.
2.4 Multiple spectra de novo peptide problem and its develop-
ment
De novo peptide sequencing methods have existed for several decades, but there are still challenges in cor-
rectly identifying peptide sequences. Traditional de novo peptide sequencing methods use only one MS/MS
spectrum to conduct peptide sequencing. The main shortcoming of these approaches is the limited frag-
mentation information extracted from only one experimental spectrum. Therefore, identication accuracy
is limited. Apart from using new and high quality spectra for sequencing, there is another way to improve
performance, which is to combine multiple spectra from the same peptide but from dierent technologies to
conduct de novo sequencing [74]. For instance, CID (and/or HCD) and ExD spectra belonging to the same
precursor can be paired to obtain more fragmentation information for peptide sequencing [75, 76]. The use
of a pair of spectra is the major focus of multiple spectra peptide sequencing.
In CID fragmentation, b-ions and y-ions are the primary results from cleavage of the peptide bond, while
ExD fragmentation has no preferred cleavage sites except proline, which leads to a more uniform distribution
of the fragment ions, mainly consisting of c-ions and z-ions. In addition, CID fragmentation tends to produce
more fragment ions from cleavages in the middle of the sequence while ExD fragmentation prefers cleavages
at the end of the sequence [77]. This makes CID and ETD perfectly complementary techniques and leads to
a more comprehensive coverage of a peptide sequence with fragment ions [78].
In the following, some major developments of utilizing multiple spectra for de novo peptide sequencing
are discussed and compared. Although the current trend is to use a pair of spectra, some of the methods
introduced below have the potential or are already able to utilize three or more spectra.
To our knowledge, the earliest method designed for multiple spectra sequencing was the one developed
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by Savitski et al. [79]. This method utilizes spectra of the same peptide from collision activated dissociation
(CAD) and electron-capture dissociation (ECD) together. Their algorithm rst uses ions that have supporting
ions in the other spectrum to create a backbone of the sequence, then uses complementary ion pairs and
other ions from the two spectra to extend the sequence until a full sequence is obtained. This is a linear
greedy algorithm that can be readily computed.
Other methods that fall into this category include CompNovo [77], Spectrum Fusion [80], pNovo+ [75], and
NovoPair [81]. CompNovo [77] employs a divide-and-conquer approach combined with a mass decomposition
algorithm. It uses informative ions from CID spectra to separate the whole spectra into suitably-sized
segments controlled by the divide-and-conquer criteria. It lists all possible amino acid compositions (AACs)
and compares them with the two experimental spectra to infer the peptide sequence that generated the
spectra. Spectrum Fusion [80] is proposed as a generic algorithm for multiple spectra sequencing. It combines
multiple spectra into a synthetic spectrum, and conducts de novo sequencing using the synthetic spectrum.
The method was evaluated on CID and ETD spectra pairs [80], but the method framework is applicable
for more and other types of spectra. In addition, this method includes a parent peptide correction strategy,
which is essential in solving multiple spectra sequencing problem.
CompNovo and Spectrum Fusion are more suitable for CID and ExD spectra because of the features they
consider, while the latter two, pNovo+ and NovoPair, are designed for HCD and ExD spectra. pNovo+ rst
uses an oset frequency function (OFF) from Sherenga [56] to learn all ion types considered in the algorithm,
and then uses isotopic clusters to determine ion charge and convert all ions to +1 form to simplify subsequent
calculations. After this, the algorithm builds a spectrum graph and nds k longest paths (keeping just the k
longest paths from 0 to the current vertex every time), inferring the peptide sequences from them. NovoPair
uses a new spectrum graph model (GMET) developed from [73] and considers dierent fragment ion types
occurring in both spectra. It uses length-three peptide tags to separate a peptide into small regions, and
integrates amino acid composition (AAC) information into the graph model.
Apart from combining information from multiple spectra from the same subsequent peptide for pep-
tide sequencing, there are other ways of utilizing the information. He and Ma [31] presented the algorithm
ADEPTS that includes a new scoring function to select the best peptide candidates from the sequencing
results output by traditional methods; for example, candidates produced by the PEAKS [62] software for
each of two spectra. This method does not try to combine information from multiple spectra to design
a new sequencing method, but rather focuses on a new scoring function designed to select the correct se-
quences from all candidates. The hypothesis of ADEPTS is that the correct sequence is already generated
by single-spectrum sequencing methods, and the only need is a good selection scheme to nd that correct
one. Therefore, ADEPTS is expected to have good performance for the case that at least one of the multiple
spectra is of good quality. ADEPTS has implemented a new way of using multiple spectra for de novo peptide
sequencing that integrates conveniently with current peptide sequencing algorithms. It also has the potential
to be extended to the case of more than two spectra.
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There are other studies that use multiple spectra, and we just give a brief introduction here. Altelaar
et al. [82] utilized a special enzyme to break the peptide backbone at the N-terminal side of lysine residues,
and combined CID and ETD spectra to conduct peptide sequencing. Guthals et al. [83] used MS/MS
triplets (CID/HCD/ETD) from overlapping peptides produced by dierent enzymes to infer peptide or even
protein sequences. The longest sequence from their experiments is up to 200 amino acids. Shen et al. [74]
compared the peptide sequencing performance of dierent methods when using various types of spectra solely
or together. Recently, Jeong et al. [84] proposed a universal de novo sequencing tool based on spectrum graph
model and claim it can be used for various types of spectra.
2.4.1 Discussion
The use of multiple spectra has become popular in the past decade and major attention has been paid to
the use of a pair of spectra from the same peptide. There are still a limited number of methods available
for this problem, and often it is hard to determine the superiority among them. Both CompNovo [77] and
Spectrum Fusion [80] have been shown to achieve better peptide sequencing results on various experimental
datasets compared to those methods that only use a single spectrum such as PEAKS [62] and PepNovo [59].
ADEPTS has shown better performance compared to both PEAKS and CompNovo [31]. NovoPair claims
to outperform pNovo+ in terms of full length peptide sequencing accuracy on three dierent experimental
dataset pairs [81]. It is important to notice that the above conclusions are based on dierent experimental
data used in each study, and due to dierences in properties of the data, these comparisons are not necessarily
comprehensive and conclusive.
Despite the limitations, all the introduced multiple spectra sequencing methods have opened a new door
for de novo peptide sequencing and provide a promising way to solve some of the current challenges facing
traditional de novo peptide sequencing methods. Since most of the recent methods are mainly focused on
a pair of spectra, the extension of these algorithms to more spectra can be a major focus for future study.
When more types of data are available with improvements in fragmentation technique, we should be able to
apply the current algorithms to them with proper modications. For example, the algorithm developed by
He and Ma [31] can be easily applied to more spectra with a small change of scoring function. In addition,
more spectrum-specic features should be investigated and applied in the methods using multiple spectra.
Currently, some methods mainly use mass-based features [77,79] and some use intensity-based features [31].
These features are usually used to extract information from all spectrum types. They are general features
common to all spectra and not spectrum-specic features. By leveraging spectrum-specic features, such as
IMs and internal fragments in HCD spectra, we may be able to extract more information from a spectrum
and achieve better sequencing results. Finally, since the use of pairs of MS/MS spectra have been applied to
database search [85,86], combination approaches of de novo sequencing and database searching using multiple
spectra are promising as a future study direction.
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2.5 Conclusions and outlook
De novo peptide sequencing has evolved over several decades and numerous methods have been published.
This paper reviewed recent developments in the area, especially methods developed for new types of MS/MS
spectra. The paper rst introduced background knowledge on peptide sequencing and principles of the
experimental instrument, and then reviewed de novo peptide sequencing methods for traditional CID spectra.
After that, it summarized recent developments in de novo sequencing using alternative spectra, with the focus
on the methods using a single spectrum and multiple spectra from the same peptide.
Dierent algorithms and software have their respective advantages and disadvantages, and it is unfair to
say that one categorically surpasses all others. At the same time, there are still problems and limitations
in current methods [87]. In light of the problems, the following are some future work directions that we
believe would be worth considering. Firstly, since an MS/MS spectrum is noisy and with missing data,
improved preprocessing methods applied before peptide sequencing would be quite useful [88{90]; for example,
preprocessing methods for alternative MS/MS spectra. Secondly, since some algorithms are highly dependent
on an accurate parent peptide mass, more strategies can be used to improve that mass accuracy. Thirdly, in
the use of m=z ratios, many current algorithms have not considered various charge states (diering values
of z). Since multiple charges occur often in MS/MS, especially in ExD spectra [17], charge determination
methods would be quite useful to assist with de novo peptide sequencing [91{93]. Fourthly, for the multiple
spectra case, more eorts can be put toward new method development and performance comparisons among
dierent methods. Finally, for the combination of dierent methods, more eective ways can be devised to
combine de novo peptide sequencing with database searching; for example, Zhang et al. [64] give a new way to
combine the two kinds of methods. Also, some tag-based methods have been applied in the combination of de
novo peptide sequencing and database searching [69,70,73]. Researchers can work on multiple tag generation
in these methods and cleavage determination of those tags, both of which could improve the performance of
this combination of methods.
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Chapter 3
NovoHCD: De novo peptide sequencing from HCD spec-
tra
Published as: Yan Yan, Anthony J. Kusalik and Fang-Xiang Wu. \NovoHCD: De novo peptide sequencing
from HCD spectra," IEEE Transactions on NanoBioscience, vol.13, no.2, pp.65-72, June 2014.
In the previous chapter, a comprehensive review of de novo peptide sequencing methods for MS/MS
spectra is given. Findings and analysis in it point out limitations and gaps in current methods available and
suggest potential directions for improvements and new method developments. Therefore, in this chapter, a
study of a new de novo peptide sequencing method for HCD spectra is presented.
It is mentioned in the previous chapter that with the development of MS/MS fragmentation techniques,
new types of MS/MS spectra are available and computational methods designed for them have been developed.
However, current methods often fail to build satisfying models that eciently extract information from HCD
spectra. New models that are suitable for HCD spectra better are needed.
In this chapter, a de novo sequencing method including a new type of spectrum graph model is presented.
This graph includes multiple types of edges representing dierent kinds relationships between two ions in a
spectrum. Amino acid composition information and peptide tags are used in this method to limit the size
of the graph and simplify the calculation in the peptide sequencing. Experimental results on several HCD
spectral datasets show that the proposed method, NovoHCD, outperforms other competing methods in terms
of full length sequencing accuracy.
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Abstract
In recent years, de novo peptide sequencing from mass spectrometry data has developed as one of the major
peptide identication methods with the emergence of new instruments and advanced computational methods.
However, there are still limitations to this method; for example, the typically used spectrum graph model
cannot represent all the information and relationships inherent in tandem mass spectra (MS/MS spectra).
Here, we present a new method named NovoHCD which applies a spectrum graph model with multiple types
of edges (called a multi-edge graph), and integrates into it amino acid combination (AAC) information and
peptide tags. In addition, information on immonium ions observed particularly in higher-energy collisional
dissociation (HCD) spectra is incorporated. Comparisons between NovoHCD and another successful de novo
peptide sequencing method for HCD spectra, pNovo, were performed. Experiments were conducted on ve
HCD spectral datasets. Results show that NovoHCD outperforms pNovo in terms of full length peptide
identication accuracy; specically, the accuracy increases 13%{21% over the ve datasets.
3.1 Introduction
There is growing interest in the identication of peptide sequences on the proteome-wide scale. Tandem
mass spectrometry (MS/MS) has emerged as a major technology for peptide identication [5,6]. In a typical
MS/MS experiment, protein mixtures are rst digested into suitably sized peptides for mass spectrometric
analysis using site-specic proteases (usually trypsin). Then the peptides are ionized via an ionization
process. After that, selected peptides are further broken into fragment ions, and their tandem mass spectra
are collected [8{11].
In MS/MS, peptide ions are fragmented into various kinds of fragment ions, named a-, b-, c-, x-, y-, and
z-ions. Dierent fragmentation techniques used in MS/MS yield diering dominating types of fragment ions.
Collision-induced dissociation (CID) is one of the most commonly used fragmentation techniques, and it yields
b-ions and y-ions as dominating ions. Higher-energy collisional dissociation (HCD) has similar dominating
ions to CID but with more abundant ions in the low mass region (typically  200Da). Specically, there are
special types of ions shown on HCD spectra, and the most informative ones are immonium ions (IMs) [36].
Other useful ions include b1-ions, y1-ions, and a2=b2-ion pairs. There are also other types of fragmentation
techniques, such as electron capture dissociation (ECD) and electron transfer dissociation (ETD). These
preferentially produce variants of c-ions and z-ions, and occasionally a-ions, and thus can be viewed as the
complement of CID or HCD [31].
There are two kinds of methods widely used for peptide sequence identication from MS/MS data:
database searching and de novo sequencing. In database searching, theoretical spectra are computed from
an existing protein database and peptides are identied by matching the theoretical spectra to experimental
spectra. The major disadvantage of database searching is that it cannot identify new, currently unknown
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peptides since a prior database is always needed. De novo sequencing, on the other hand, estimates peptide
sequences without the help of a database; it automatically interprets spectra using the masses of amino
acids. Therefore, this method can identify new proteins, proteins resulting from mutations, proteins with
unexpected modications and so on. During recent years, especially with the development of high mass
accuracy MS/MS, de novo sequencing has drawn increasing attention [48]. Therefore, this study focuses on
the improvement of de novo peptide sequencing.
In de novo peptide sequencing, spectrum graph modeling has proven to be quite successful and hence
has been widely used [21, 52, 59, 62, 72]. In this approach, a tandem mass spectrum is typically represented
as a graph. Each fragment ion, corresponding to a peak in a spectrum, is represented as a vertex and two
vertices having a mass dierence equal to one amino acid mass are connected by an edge. The main idea
of this method is to nd paths in the graph that represent peptide sequences potentially giving rise to the
spectrum.
There is another method used in the peptide sequencing called sequence tagging that comprises a middle
path between database searching and de novo sequencing [21, 22]. Peptide tagging rst outputs partial
sequences, usually called tags, from a MS/MS spectrum, and then uses these tags to search against a protein
database to interpret the spectrum. The use of tags can dramatically reduce the search space and time
needed, which makes it popular for some peptide identication problems. In addition, peptide tags also
have the potential to help de novo peptide sequencing since it provides useful information of partial peptide
sequences.
With the appearance of alternative MS/MS data resulting from dierent fragmentation techniques, novel
computational methods have emerged to enhance de novo peptide sequencing performance [94]. pNovo [72],
which applies a spectrum graph model and combines IM and internal fragment ion information from HCD
spectra, has achieved superior peptide sequencing results. Its performance on various testing data has been
shown to be better than that of two previous algorithms, PEAKS [62] and PepNovo [59]. Other research
has focused on the ability of pre-processing and charge determination in ETD spectra to improve sequencing
results [66]. Another popular approach is combining dierent types of spectra from the same peptide to
achieve better results [74]. For instance, CID (and/or HCD) and ETD (or ECD) spectra belonging to the
same precursor can be paired to obtain more fragmentation information for peptide sequencing [75,76].
Although de novo peptide sequencing has improved with the advance of instruments and computation,
it still has shortcomings, especially the limited amount of information extracted from the spectrum graph
model. For example, in a traditional spectrum graph, an edge is drawn between two vertices only when the
mass dierence between the two vertices is equal (or close) to one of the 20 amino acid masses. Then if
there are peaks missing in the spectrum or the m=z values are inaccurate, it could be very dicult to nd
a path from the graph representing the correct peptide sequence. Therefore, a more suitable model with
more information included is very appealing. Since the traditional model only considers amino acid mass
dierence, a multi-edge graph that includes multiple relationships from MS/MS spectra is expected to have
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better performance [21].
Natural choices for extracting more information from a spectrum are peptide tags and amino acid combi-
nations (AACs). Peptide tags provide information about partial peptide sequences, information that would
denitely be useful to de novo peptide sequencing. AAC, which consists of order-independent amino acid
composition for a peptide, is also quite helpful [95, 96], especially in limiting the edges of a spectrum graph.
In general, graph-based algorithms compute the mass dierence between the two vertices and compare it with
the theoretical residue mass of the 20 amino acids. However, in practice, a peptide usually does not contain
all 20 amino acids. In addition, due to the high noise level of the MS/MS spectra, wrong matches of amino
acids can easily happen if we compare with all 20 possible masses. When the correct AAC is known, instead
of considering all 20 amino acids, only those in the AAC set are considered when determining whether there is
an edge between two vertices. Therefore, identifying the proper AACs can ultimately reduce computational
time and eliminate false positive edges in a spectrum graph.
In this paper, we present a new method, NovoHCD, which uses a modied spectrum graph model with
multiple types of edges (called a multi-edge graph) for peptide sequencing. It is developed from [21, 94] and
combines amino acid combinations (AACs) and peptide tags to infer peptide sequences. The remainder of
this paper is organized as follows. Section 2 presents the proposed de novo sequencing method. Section 3
describes performance experiments and results. Finally Section 4 concludes the paper and gives future work.
3.2 Methods
The proposed method, NovoHCD, rst uses peptide tags to break the whole peptide sequencing problem into
three parts: sequencing of tags, prexes, and suxes of the peptide. That is, the peptide sequence being
inferred is separated into three parts (prex, tag, and sux). The method builds separate multi-edge graph
models for each prex and sux, and AAC information is used to limit edges of each graph. This method
then combines these three parts to output complete sequences of candidate peptides. In addition, immonium
ions observed particularly in HCD spectra are used in the candidate peptide ranking step. The method ow
chart is shown in Figure 3.1.
3.2.1 Multi-edge graph model
In the new multi-edge graph G = (V;E), each peak (corresponding to a fragment ion) in the experimental
spectrum is represented as a vertex v and its mass to charge (m=z) value is denoted as mv. In the following,
unless otherwise specied, we assume that the fragment ions have z = 1. A is taken to be the set of 20 amino
acids, and ai 2 A is a certain amino acid. ai is also used to represent its residue mass. mloss is dened to
be the mass of some small molecules lost from fragment ions, which typically include H2O, NH3, CO- and
NH- groups. For a string of amino acids P = a1a2 : : : an, dene jP j to be the mass sum of all amino acids in
P . Thus jP j = Pni=1 ai. Then the mass of parent peptide P (denoted as mP ) becomes mP = jP j +mH2O,
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Find qualified peptide tags 
Put in set T in order  
Select first t, delete it from T; 
Calculate Δmpre, Δmsuf   separated by t  
Calculate AACs for Δmpre, Δmsuf 
Apply multi-edge graph model under each AAC 
Combine partial sequences from prefix, tag, and suffix 
 
Start 
Have unused tags 
in T?  
No Yes 
Check tags 
Stop 
Assemble all parts to be candidate sequences. 
Store them into set Candidate 
Infer sequences from each graph 
 
Output ranked 
sequences 
Rank sequences in 
Candidate  
 
Figure 3.1: Method ow chart. All peptide tags are stored in set T , and t represents a tag in T ;
mpre and msuf represent the mass values of the prex and sux separated by t, respectively.
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and the mass sum of a pair of complementary ions (charge +1) derived from P , denoted as M , becomes
M = mP + 2. The above notions are similar to those used in [63]. 8u; v 2 V , the following types of edges
are considered in G.
1. Type 1 edge, e1uv: A directed edge e
1
uv is drawn from u to v when j (mv  mu)  ai j 1, where 1 is
a given threshold. We label e1uv with ai. Here, vertex u and v are expected to have a mass dierence
of a single amino acid, ai. This is the type of edge dened in a traditional spectrum graph.
2. Type 2 edge, e2uv: An undirected edge e
2
uv is drawn between u and v when j M   (mv +mu) j 2,
where 2 is a given threshold. Here u and v are viewed as complementary ions.
3. Type 3 edge, e3uv: An undirected edge e
3
uv is drawn between u and v when j (mv +mu) M   ai j 3,
where 3 is a given threshold. We label e
3
uv with ai.
4. Type 4 edge, e4uv: An undirected edge e
4
uv is drawn between u and v when jM   (mv +mu)  ai j 4,
where 4 is a given threshold. We label e
4
uv with ai.
5. Type 5 edge, e5uv: A directed edge e
5
uv is drawn from u to v when j (mv  mu) mloss j 5, where 5
is a given threshold. Here u and v are dierent ions from the same cleavage site of the peptide.
All  values mentioned above are specied by the user. For the HCD spectra used in the experiments
of this paper, all  values were set to be 0.01Da. Figure 3.2 shows (part of) a multi-edge graph. In this
graph, vertices u and v have a mass dierence of ai, and v and t have a mass dierence of aj . uc, vc and tc
are complementary ions of u, v and t, respectively. uloss, vloss, tloss, uc loss, vc loss and tc loss represent
any loss of small molecules from u, v, t, uc, vc and tc, respectively. In this graph, Type 1 edges are black
with arrows, Type 2 edges are blue, Type 3 edges and Type 4 edges are purple and green, respectively, with
arrows and Type 5 edges are red with arrows. One can see that, except for Type 2 and Type 5 edges, all
other edges have amino acids labeling them, and one amino acid can be inferred through all vertices from
the same cleavage site of the peptide. For example, in Figure 3.2, amino acid ai can be inferred from the
vertex set V Suv = fu; v; uc; vc; uloss; vloss; uc loss; vc lossg. The vertices uloss; vloss; uc loss; vc loss represent
just one kind of small neutral loss, and in real experiments, dierent kinds of losses may occur and there
would be more vertices representing small neutral losses in the multi-edge graph.
Here, we dene the graph induced by all vertices from the same cleavage site of the peptide as a basic
structure of the multi-edge graph G, denoted G[V S]. From each G[V S], an amino acid ag is expected to be
inferred. Therefore, we add this amino acid into the notion of the basic structure, and denote the result as
G[V S ag]. From connected basic structures in G, consecutive amino acids can be inferred. Here, \connected
basic structures" means that for any basic structure G[V S   ag] belonging to the whole structure, there is
at least one other basic structure G[V S   ah] having vertices overlapping with G[V S   ag]. For example, in
Figure 3.2, G[V S   ai] and G[V S   aj ] are connected basic structures that have v, vc, vloss and vc loss as
overlapping vertices.
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Figure 3.2: An example of a multi-edge graph.
Another graph GAA can be used to represent the relationship of amino acid strings inferred from basic
structures, in which the vertices VAA and edges EAA are dened as below.
VAA: Each vertex represents an amino acid acquired from a basic structure of a multi-edge graph.
EAA: Two amino acids are connected by an undirect edge if they are inferred from two connecting basic
structures.
With the multi-edge graph G and the basic structures G[V S], the peptide sequencing problem is then
transformed into a path-nding problem in a simple graph GAA.
During a MS/MS experiment, spectra representing dierent kinds of ions, along with their loss of small
molecules, are created. Assuming that there are  types of ions present, the set of these ions is dened as
 = f1; 2; : : : ; g: (3.1)
For a peptide P = a1a2 : : : an, in order to nd its full length sequence using a spectrum graph model, at
least one  ion should be observed at each cleavage site between amino acid ai and ai+1, 8i 2 1; 2; : : : ; n  1.
In the traditional spectrum model, only two kinds of ions, b-ions and y-ions, are considered when nding
the longest paths. Here, 8 more types of ions are considered in the multi-edge graph model including loss of
H2O, NH3, CO- and NH- groups of both b-ions and y-ions. Therefore, the multi-edge graph model has a
higher chance of interpreting the full length peptide sequences than the traditional model.
3.2.2 Integration of peptide tags and AAC information
With more types of ions considered, the computational time and the possibility of false positives could be
increased. As a solution to this problem, more information from MS/MS spectra can be integrated into the
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model. Here, peptide tags and AAC information are incorporated into the proposed model.
Since peptides are long strings of amino acids, a straight-forward idea to make the sequencing problem
easier would be cutting the long strings into shorter, more easily interpreted substrings, and then solving
the sequencing problem on these shorter strings. Here, NovoHCD uses peptide tags to separate the whole
peptide sequences into three parts, namely prex, tag, and sux, and then uses the multi-edge graph model
on both prex and sux with AAC information to limit the number of edges considered in the multi-edge
graph model.
Currently, the most widely used peptide tags are 3-tags (tags consisting of three amino acid residues) [22].
Since the major focus of this paper is multi-edge graph based peptide sequencing and not tag nding, and
there are already many tag-nding algorithms available, a suitable 3-tag generating algorithm is chosen to
output all tags needed in the proposed method. An eective method named DirecTag [22] is used. For the
AAC information, an in-house database was built containing all theoretically possible AACs for any given
mass of no more than 3000Da, which should be able to output the AACs for almost all peptides encountered
in a peptide sequencing problem.
The detailed procedure of inferring peptide sequences from the multi-edge graph model with AAC infor-
mation and a given peptide tag t is summarized in Algorithms 1 and 2. The following notions are used in
the algorithms. T is the set of all tags, S = f(mi; inti) j i = 1; 2; : : : ; ng is the peak list of an experimental
spectrum. PreSeq and SufSeq are the sequence sets of the possible prex and sux sequences of the original
peptide separated by tag t, respectively. mpre and msuf represent the mass values of the prex and sux
separated by t, respectively. G([V;E]) is a multi-edge graph representing the various relationships between
ions, where each vertex in V is a peak in S. G[V S] is a basic structure of G([V;E]). Anow is the AAC used
in the path nding in the current multi-edge graph G([V;E]).
Algorithm 1 Peptide sequencing using multi-edge graph model with integration of AACs and known peptide
tags
Input: A tag t 2 T , experimental spectrum S = f(mi; inti) j i = 1; 2; : : : ; ng, mpre and msuf .
Initialize: G([V;E])0 ( [Ion; ;], Candidate( ;.
Calculate AACs of mpre and msuf , and put into sets AAC
pre and AACsuf
Calculate the m=z values of rst and last ions of t, denoted as m(it)s and m(it)e
Invoke Algorithm 2 with input AACpre and m(it)s, yielding PreSeq
Invoke Algorithm 2 with input AACsuf and m(it)e, yielding SufSeq
for all seqp 2 PreSeq do
for all seqs 2 SufSeq do
Combine seqp and t and seqs, and put it into Candidate
end for
end for
Output: Candidate.
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Algorithm 2 Partial peptide sequence generation based on multi-edge graph model and given AACs
Input: Set of AACs A, m=z values of ion m(it).
Initialize: Set of paths Seq ( ;.
while A 6= ; do
Put rst AAC in A into Anow
G([V;E])( G([V;E])0, V next( m(it)
while V next 6= ; do
Put rst vertex in V next into u
for all mi 2 V do
Check if any edges of types e1uv to e
6
uv can be drawn when using Anow between u and mi, and let e
be the number of such edges
Add the e edges to E
Add the vertices connected with u into V next
end for
end while
Find basic structures G[V S] in G([V;E]) and build induced graph GAA
Infer paths from GAA qualied by Anow
Add qualied paths into Seq
Delete Anow from A
end while
Output: Set of paths Seq.
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Table 3.1: Description of mass-based features used in tag ranking
Feature of v number of ions u in a spectrum where
f1 u is the complementary ion of v.
f2 u and v are the +1 and +2 charges of the same partial peptide.
f3 u has a mass dierence of a single amino acid to v.
f4 u has a mass dierence of a loss of a small molecule from v.
f5 u and v are isotopic pairs.
f6 mass sum of u and v is close to parent mass with one amino acid loss or overlap.
3.2.3 Ranking of peptide tags
The peptide tag nding algorithm employed by DirecTag contains a criterion for ranking the output tags.
However, under scrutiny this ranking criterion was determined to be not very eective, thus limiting the
performance of NovoHCD. Therefore, a new peptide tag ranking method is developed here in order to pick
the best tags more eectively.
The proposed ranking method borrows ideas from the multi-edge graph model when choosing mass-based
features, and also the idea of \local maximum" from other research conducted by our group [88] when
applying intensity information to feature calculation. This method rst calculates the rank of each peak in
a spectrum, and then combines ranks of all four peaks forming a tag to be the rank of the tag. This ranking
method utilizes information not considered by DirecTag, and thus is expected to achieve better results. In
this method, six mass-based features, denoted as F = [f1; : : : ; f6], are rst generated. These features are all
numbers of ions satisfying the criteria listed in Table 3.1. Calculation of a nal score for each ion v, denoted
as F (v), is dened as the linear combination of all features,
F (v) =
6X
s=1
X
u2Env
fs(u; v)  ws; (3.2)
where ws is the weight of fs, and E is the edge set of the graph G. The weight vector W = [w1; : : : ; w6] =
[1; 0:5; 1; 0:2; 0:5; 1] is dened similarly to the weight assignment method used in [88].
It has been shown that a simple threshold is not eective in dierentiating signal ions from noisy ions
because the ions' intensities in a spectrum tend to be larger in the middle of a m=z range than at the two
ends [88]. Rather, it is more reasonable to assume that the noises in a narrow m=z range are described by a
single simple distribution (for example, a normal distribution) and that the signal ions tend to be the local
maxima [88]. In this circumstance, we dene local maximum and order in the use the intensity of each ion v
as follows.
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Local maximum: Vertex v is called a \local maximum" if its intensity is larger than the two peaks beside
it.
Order : The order of vertex v, denoted as o, is the iteration on which it is picked as a local maximum in
the following procedure. o = 1 means the peak is a local maximum of the original spectrum. After deleting
these o = 1 peaks, the local maximum peaks from the remainder of the spectrum will be assigned orders
o = 2. This process repeats iteratively until all peaks have been assigned with an order.
Finally, in the ranking process, an ion v with order o can be represented as a vector R(o; F (v)). We order
R rst according to its initial element o in an increasing order, and then F in a decreasing order if two o
values are the same. After this ranking process, each v has its rank, denoted as rv. If a tag T consists of four
ions vi, vj , vk, and vt from the original experimental spectrum, the rank of T , denoted as rT , is calculated as
rT = rvi + rvj + rvk + rvt : (3.3)
The smaller the value of rT , the greater the chance that tag T is selected in the proposed method.
3.2.4 Candidate peptides scoring scheme
When all candidate peptides have been generated, the last step of NovoHCD is to rank these candidates
and determine the most likely correct candidates. Parent peptide mass mP is a widely-used feature to lter
out incorrect candidates or bound the search space. Therefore, the mass dierence between candidates and
precursor ions (given in the spectrum), denoted as mP , is used as a key feature in the ranking. In addition,
IMs can be observed in HCD spectra, and possible amino acids can be inferred from these ions. Each IM
corresponds to a single amino acid. All amino acids inferred from IMs observed in a spectrum are dened as
AAIM , and the number of amino acids in AAIM that are included in the candidate sequence is dened as
NIM . Therefore, for a given spectrum, each candidate peptide generated by NovoHCD can be represented
as a vector CP (NIM ;mP ). An approach similar to the one in the proposed tag ranking method is then
used. It rst sorts CP according to its initial element NIM in a decreasing order, and then arranges mP
in an increasing order. After this process, each candidate and its nal ranking is output.
3.3 Experiments and Results
Five MS/MS datasets were used to test the performance of the proposed method. The performance was then
compared with that of another de novo peptide sequencing algorithm for HCD spectra named pNovo [72].
The detailed experimental process and comparison results are presented below.
3.3.1 Datasets
Five datasets were used to investigate the performance of our new method and pNovo. The rst dataset,
SwedHCD contains +2 charged high-energy (HCD) MS/MS spectra of unique peptides [97]. The other
29
four datasets { SCX decon, SCX nodecon, 60min analyses, 300min analyses { are from the same research
paper [98]. The original datasets contain various fragmentation MS/MS spectra including CID, HCD, and
ETD spectra. The HCD spectra were selected from them for the experiments here. The number of spectra
from the above ve datasets used in the analysis were 10878, 1952, 2557, 123 and 154, respectively. Spectra
from the latter four datasets have charges of +2, +3, and +4.
To determine correctness of the peptides produced by the two programs for each input spectrum, a \gold
standard" was necessary. Every spectrum in the ve datasets came with a correct spectrum. To give a more
comprehensive comparison, sequences from Mascot were also used as correct peptide sequences. Mascot [99]
is a widely-used program for protein identication based on database search. All results produced by Mascot
were trimmed to a < 5% false discovery rate.
3.3.2 Peptide tags ranking performance
The performance of the peptide tag ranking methods was rst investigated: our proposed method versus
DirecTag. The SwedHCD dataset was used for this. For each spectrum, DirecTag produced 50 tags with
their rankings. To evaluate the two methods, we compared the number of spectra having at least one correct
tag under the condition of the same number of tags selected. The comparison when selecting at most 30 tags
per spectrum is shown in Figure 3.3. The y-axis in Figure 3.3 is the number of spectra having at least one
correct tag.
Sequences from Mascot were used as the correct sequences when generating the results in Figure 3.3.
Using the correct sequences as supplied by the databases gave similar results (data not show). Figure 3.3
shows that given the same number of (top-ranked) tags selected, more spectra contain at least one correct
peptide tag using NovoHCD. For example, when selecting 30 tags for both methods, there were 9,384 spectra
having at least one correct tag by using NovoHCD, while the number was 9,176 by using DirecTag's ranking
criterion. Similarly, if we set the number of peptides having at least one correct tag to be the same, NovoHCD
needed fewer tags output. For example, when setting the peptide number to be 9,176, NovoHCD needed no
more than 21 tags per spectrum, while the DirecTag needed 30 tags per spectrum.
The proposed ranking method makes a signicant contribution to the whole proposed multi-edge graph
based method. Using this ranking method, higher peptide sequencing accuracy can be achieved with fewer
tags, which corresponds to fewer multi-edge graphs calculated and fewer candidate peptides generated. Thus,
the computational costs and number of false positive candidate peptides can be reduced by using the proposed
ranking method.
3.3.3 De novo peptide sequencing performance
All ve datasets were used to investigate the performance of the proposed method and pNovo. For each
spectrum, the top three candidates output by NovoHCD and pNovo were selected for evaluation. If any one
of the three candidates was correct, we said that this spectrum achieved a full length accuracy for the given
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Figure 3.3: Performance comparison of NovoHCD's ranking method (solid green curve) and DirecTag
ranking (dashed blue curve).
method. The results for the full length peptide sequencing accuracy comparison are presented in Tables 3.2
and 3.3 with the use of Mascot and datasets providing correct sequences, respectively.
From Tables 3.2 and 3.3 one can see that for all ve datasets, NovoHCD achieves higher full length
accuracy than pNovo, and the improvement ranges from 13% to 21% on dierent datasets. On SwedHCD
dataset, both methods achieved highest full length accuracy. This could be because this dataset only contains
+2 charged peptides, which makes the spectra less complex and easier to process. In addition, both methods
achieve lowest accuracy on the 300min analyses dataset. This might be due to the low quality of the spectra,
but further investigation is needed to get a reliable explanation. On the 60min analyses dataset, the two
methods have the largest accuracy dierence, which might be because that +3 and +4 charged spectra make
the sequencing problem more complicated. In this case, NovoHCD considers the +2 charged ions, which
occur more commonly in +3 and +4 spectra, thus making its sequencing result better than pNovo's. Other
features from +3 and +4-charged peptides will be further studied to improve our method in future study.
Furthermore, we considered the relationship between the number of correctly identied peptides and
peptide length. Figures 3.4 and 3.5 summarize the results from comparing the outputs of NovoHCD and
pNovo on the two largest datasets of the experiments, SwedHCD and SCX nodecon, respectively.
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Table 3.2: Full length peptide sequencing accuracy comparison among dierent datasets with Mascot
results as correct sequences
Dataset pNovo NovoHCD
SwedHCD 80.93% 94.50%
SCX decon 65.89% 81.46%
SCX nodecon 77.90% 88.46%
60min analyses 60.87% 81.52%
300min analyses 53.44% 67.17%
Table 3.3: Full length peptide sequencing accuracy comparison among dierent datasets with se-
quences from datasets as correct sequences
Dataset pNovo NovoHCD
SwedHCD 80.95% 94.54%
SCX decon 63.11% 80.58%
SCX nodecon 73.99% 85.14%
60min analyses 61.79% 81.30%
300min analyses 50.65% 67.53%
Figures 3.4 and 3.5 show that NovoHCD identied more peptides at every peptide length, as compared
to pNovo. The most peptides identied have lengths 8 to 10 with the SwedHCD dataset, and 13 to 16 with
the SCX nodecon dataset. In addition, the SCX nodecon dataset has longer peptides than the SwedHCD
dataset, and an increase of peptide length corresponds to fewer correct peptides inferred by both methods.
One can see that for length larger than 25 in the SCX nodecon dataset, almost no peptides were correctly
identied by either method. Therefore, long peptide sequencing is still a challenging problem in de novo
peptide sequencing. NovoHCD, which breaks whole peptides into three shorter parts and then infers their
sequences, partly solves this problem, thus achieving better full length sequencing results when compared to
pNovo.
Finally, we examine the computational time of NovoHCD. The algorithm was written using Matlab
(2010b) and the program was run on a PC with a 3.07 GHz quad-core CPU (Windows 7 operating system).
The results for dierent datasets are shown in Table 4.8. All run times (CPU times) are given in seconds.
From Table 4.8 one can see that the computational time varies from dataset to dataset, but all in an
acceptable time range. The time dierence may be due to varied properties of the datasets, such as the
number of peaks per spectrum and the quality of the spectra. Reducing computational time will require
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Figure 3.4: Relationship between the number of correctly identied peptides and peptide length for
NovoHCD and pNovo using the SwedHCD dataset.
investigation to nd the most time-consuming spectra or algorithm steps. Such investigation will be part of
our future study of this de novo peptide sequencing approach.
3.4 Conclusions and future work
In this paper, a new solution to the de novo peptide sequencing problem for HCD spectra, NovoHCD, has
been proposed. It is based on multi-edge graphs with integration of AAC and peptide tags. NovoHCD rst
uses peptide tags to separate a whole peptide sequence into three parts: prex, tag, and sux. It then
builds multi-edge graph models on prex and sux information separately for sequence interpretation, and
AAC information is used in limiting edges of the graph. It nally combines these three parts to generate
complete sequences of candidate peptides. Immonium ions observed particularly in HCD spectra are used
in the candidate peptide ranking of NovoHCD. Five HCD spectra datasets were used to investigate the
performance of NovoHCD and compare it with another successful de novo peptide sequencing method, pNovo.
Experimental results showed that the overall accuracy increases from 13% to 21% compared to pNovo. In
addition, NovoHCD also includes a better peptide tag ranking algorithm as compared to another software
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Figure 3.5: Relationship between the number of correctly identied peptides and peptide length for
NovoHCD and pNovo using the SCX nodecon dataset.
called DirecTag, which makes the computation faster and more accurate.
We summarize the major contributions of NovoHCD in the following. First, it replaces the traditional
spectrum graph with a multi-edge graph, thus including more relationships between two peaks in a spectrum.
Secondly, it separates the whole peptide sequences into three parts, and solves each sequencing subproblem
separately. It is straightforward to think of solving a complex problem by cutting it into smaller and simpler
subproblems, but an MS/MS spectrum itself cannot be cut into pieces and interpreted since the ion signals
are intermixed. Separating a peptide sequence (used in NovoHCD) instead of its spectrum is a more suitable
approach. Thirdly, AAC information is eectively incorporated into the peptide sequencing process. AACs
have been used before in peptide sequencing, but the AACs derived from the parent peptide mass may result
in too many combinations to calculate. However, with the separation strategy above, the number of AACs
can be limited to an acceptable number. Therefore, AACs can be used in peptide sequencing with acceptable
calculation cost in NovoHCD. Last but not least, NovoHCD has been applied on a new kind of spectra (HCD),
and incorporates unique features of this kind of spectrum (immonium ions) into the sequencing method.
In future, we will focus on improving the accuracy of the proposed method by further analyzing the
wrongly identied spectra, expanding the evaluation of the new method to more MS/MS datasets, and
extending the method to other types of MS/MS spectra, e.g. ETD spectra. In addition, since a popular
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Table 3.4: Running time comparison on dierent datasets using NovoHCD
Dataset Number of spectra Total time (in seconds) Time per spectrum (in seconds)
SwedHCD 10878 3378.32 0.31
SCX decon 1952 3857.83 1.97
SCX nodecon 2557 13238.77 5.17
60min analyses 123 204.87 1.66
300min analyses 154 313.40 2.03
approach in peptide sequencing is pairing up dierent types of spectra from the same peptide to obtain more
information, we are planning to modify the model and apply it to the multiple spectra sequencing problem.
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Addendum
Amino acid combinations (AACs) are introduced and used in the proposed method NovoHCD. In order to
get all possible AACs of a certain mass value, we used computer software to generate all theoretically possible
AACs up to length k (the value of k is explained in the following content) and calculate the mass value of
each AAC. The maximum value of the AACs used is 3000Da. Since the minimum mass of the 20 standard
amino acid is around 57.05Da (glycine), the maximum length k = 53. The masses of the AACs having the
same integer part are stored into the same folded labelled with that integer number. After this process, when
all the AACs of a certain mass value are needed, we can rst check and nd the correct folder, and then
search for all needed AACs.
Biological meanings of of 5 types of edges dened in the proposed NovoHCD are listed below.
Edge Type Meaning
Type 1 u and v have a mass dierence of some amino acid.
Type 2 u and v represent a complementary ion pair.
Type 3 u and v represent a complementary ion pair with one amino acid overlap.
Type 4 u and v represent a complementary ion pair with one amino acid gap.
Type 5 u and v are the same fragment ions but with loss of a small molecule.
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Erratum
In the second paragraph of Subsection 3.2.2, \data not show" should be changed to \data not shown".
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Chapter 4
NovoExD: De novo peptide sequencing for ETD/ECD
spectra
Published as: Yan Yan, Anthony J. Kusalik and Fang-Xiang Wu. \NovoExD: De novo peptide sequencing
for ETD/ECD spectra," IEEE/ACM Transactions on Computational Biology and Bioinformatics, in press,
online available at http://ieeexplore.ieee.org/stamp/stamp.jsp?tp=&arnumber=7005483.
In the previous chapter, a new de novo peptide sequencing method for HCD spectra, NovoHCD, is
presented. NovoHCD applies a new spectrum graph model with multiple types of edges, and integrates
other information like AACs and peptide tags to help with the sequencing. Apart from HCD spectra, there
are other types of newly available spectra that have dierent properties than HCD spectra. Among them,
ECD/ETD are widely used. ECD/ETD spectra have variants of c-ions and z-ions as dominant fragment
ions, and usually produce high quality MS/MS spectra for multiple charged (+3) peptides. These features
make ECD/ETD spectra popular for MS/MS based peptide sequencing since they are quite dierent from
the traditional CID spectra and the previously studied HCD spectra.
Based on the review in Chapter 2, current studies in ECD/ETD spectra focus on property analysis of
these spectra and sequencing using them and CID spectra together. Typically, the methods designed for the
use of CID with ECD/ETD fail to fully consider the features of ECD/ETD spectra. These methods treat
ECD/ETD spectra as supplementary to CID spectra and focus on getting the information that CID spectra
are missing from the accompanying ECD/ETD spectra. At this time, less attention has been paid to de novo
sequencing methods for ECD/ETD spectra solely. Facing this situation, a suitable method using ECD/ETD
spectra alone is noteworthy.
This chapter presents a new de novo peptide sequencing for ETD/ECD spectra named NovoExD. The
success of NovoHCD presented in the previous chapter shows the eectiveness of the new designed graph
model. It is shown that with suitable improvement and modication of the model and specic feature
consideration for ECD/ETD spectra, the new method for ECD/ETD spectra achieves better performance
than other existing methods.
The proposed NovoExD in this chapter modies the graph model in the use of peptide tags and adds
corresponding preprocessing steps. To be specic about tag usage, NovoExD changes the single tag usage in
NovoHCD to multiple peptide tags. These tags work together to separate a whole peptide sequence that needs
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to be identied into smaller pieces. The method infers partial sequences separately and assemble them back
together. Computation complexity of NovoExD and the number of possible AACs can be reduced with the
use of multiple tags. When considering unique features in ECD/ETD spectra, a charge determination step
for fragment ions is designed since a lot of ions in ECD/ETD spectra have multiple charges. Experimental
results on three MS/MS spectral datasets show that NovoExD outperforms another competing method in
terms of average full length peptide sequencing accuracy.
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Abstract
De novo peptide sequencing using tandem mass spectrometry (MS/MS) data has become a major compu-
tational method for sequence identication in recent years. With the development of new instruments and
technology, novel computational methods have emerged with enhanced performance. However, there are only
a few methods focusing on ECD/ETD spectra, which mainly contain variants of c-ions and z-ions. Here, a
de novo sequencing method for ECD/ETD spectra, NovoExD, is presented. NovoExD applies a new form
of spectrum graph with multiple edge types (called a GMET), considers multiple peptide tags, and inte-
grates amino acid combination (AAC) and fragment ion charge information. Its performance is compared
with another successful de novo sequencing method, pNovo+, which has an option for ECD/ETD spectra.
Experiments conducted on three dierent datasets show that the average full length peptide identication
accuracy of NovoExD is as high as 88.70%, and that NovoExD's average accuracy is more than 20% greater
on all datasets than that of pNovo+.
4.1 Introduction
Tandem mass spectrometry (MS/MS) is used as a major tool for peptide identication in current proteomics
studies. In a typical MS/MS experiment, protein mixtures are rst digested into suitably sized peptides, and
then the peptides are ionized via an ionization process. After that, selected peptides are further broken into
fragment ions, and their tandem mass spectra (MS/MS spectra) are collected [8]. MS/MS spectra usually
contain two kinds of information for each ion detected, its mass-to-charge (m=z) value and intensity.
In a typical MS/MS experiment, peptide ions are broken into various kinds of fragment ions. There
are six kinds of commonly observed ions, namely a-, b-, c-, x-, y-, and z-ions. Dierent fragmentation
techniques in MS/MS yield dierent dominant types of fragment ions. Collision-induced dissociation (CID)
and higher-energy collisional dissociation (HCD) yield b-ions and y-ions as dominating ions. Electron capture
dissociation (ECD) and electron transfer dissociation (ETD) preferentially produce variants of c-ions and z-
ions, and occasionally a-ions [31{33]. ETD [37] is a modication of the ECD technique [38] that was designed
for dissociation of multiply protonated peptide ions in MS/MS. In this paper, we use ExD to represent ECD
and ETD spectra as a whole.
CID was the most commonly used fragmentation technique when researchers started using mass spec-
trometry for peptide sequencing. With the development of new techniques and instruments in recent years,
alternative MS/MS spectra with new features have appeared. Among these, ExD spectra have drawn increas-
ing attention because of their unique features. Specically, ExD produces high quality MS/MS spectra for
multi-charged peptides and has no strong cleavage preferences. It utilizes a lower energy pathway than CID
and HCD, thus preserving labile post-translational modications (PTMs) [39{41]. All these features yield
spectra containing useful information, and hence they have the potential to give satisfying peptide sequencing
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performance.
Currently, there are three main kinds of methods used for peptide sequencing from MS/MS data: database
searching, peptide tagging and de novo sequencing. In database searching, theoretical spectra are computed
from an existing protein database and peptides are identied by matching the theoretical spectra to experi-
mental spectra [46]. The major disadvantage of database searching is that it cannot identify new or unknown
peptides. Peptide tagging [21, 22] usually produces partial sequences, often called tags, from an MS/MS
spectrum, and then uses these tags to search against a protein database or to help with de novo sequencing.
The use of tags can dramatically reduce the search space and time needed, and has the potential to improve
de novo peptide sequencing. De novo sequencing automatically interprets spectra using the masses of amino
acids. It can identify new proteins, proteins resulting from mutations, proteins with unexpected modica-
tions and so on. With the recent development of high mass-accuracy MS/MS and alternative fragmentation
techniques, de novo sequencing has shown promising developments [48]. Therefore, this study focuses on de
novo peptide sequencing.
ExD is a new technology that has properties dierent from CID and HCD. The recent studies of MS/MS
spectra produced by ExD have focused on the characteristics of the spectra [32, 33, 39], how various PTMs
can be identied from the spectra [40], and the performance of such spectra [17,74]. When used for peptide
sequencing, ExD spectra are often paired with CID (or HCD) spectra because of the availability of the
complementary information from these spectra [31, 75, 77, 79]. Some of the methods that use paired spectra
for sequencing also come with an option to use ExD spectra alone; for example, the one introduced in [75].
These methods typically consider only a subset of the features in ExD spectra because their focus is paired
spectra sequencing. At this time, less attention has been paid to de novo sequencing methods using ExD
spectra alone, especially when compared to the ones developed for CID or HCD spectra alone. Considering
the unique features of ExD spectra and the shortage of corresponding algorithms, a suitable method designed
for ExD spectra is useful and noteworthy.
In this paper, we present a modied spectrum graph with multiple edge types, denoted as GMET,
derived from [100] to model ExD spectra. Amino acid combinations (AACs), the order-independent amino
acid composition information of a peptide, and peptide tags have already been integrated in our previous
model [73]. This new model utilizes all previously considered features as well as unique features in ExD
spectra. Since it is quite common to acquire ExD spectra from multi-charged peptide samples, multi-charged
fragment ions are frequently observed. Wisely considering and utilizing these ions can be a great help in
peptide sequencing.
The remainder of the paper is organized as follows: Section 2 presents the overall design, the GMET
model, and schemes for charge determination of fragment ions, peptide tags and amino acid usage, and
the candidate peptide ranking. Section 3 presents an evaluation of the method. Shown are the evaluation
methodology, the experimental results and performance analysis. Finally Section 4 concludes this study and
gives some directions for future work.
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4.2 Methods
In this section, a new de novo peptide sequencing algorithm for ExD spectra is proposed. The algorithm
considers unique features of ExD spectra including alternate dominant ions and multi-charged fragment ions,
and uses a recently presented type of graph, a graph with multiple edge types (GMET) [73]. The graph is
constructed by considering multiple peptide tags and fragment ion charge information.
The whole method is summarized in Figure 4.1. To start, the algorithm rst searches the low mass region
of a spectrum, typically less than 200Da (Dalton, the unied atomic mass unit), to nd any consecutive,
same-type ions from the rst two cleavage points; to be specic, ion pairs fc1; c2g, fz.1; z.2g, fc  1.1; c  1.2g,
and f(z + 1)1; (z + 1)2g. In this notion for ions, \+1" and \-1" represent addition or loss of 1Da in mass,
respectively; subscript numbers indicate the cleavage positions on a peptide backbone from either N -terminal
or C-terminal; and an ion with a dot \." means a radical fragment ion, which is a free radical species carrying
a charge. If any pair exists, the two amino acids at the ends of a peptide sequence can be inferred and the
sequencing will be conducted on the rest of the peptide sequence. The motivation of this preprocessing step is
to reduce the potential sequencing length and make the problem easier to solve. This step is shown in Figure
4.1 in a dashed box indicating that one may not nd any ion pairs for some spectra to limit the sequencing
length, especially for the spectra with poor fragmentation at the terminal amino acids.
After this preprocessing step, a tag nding and ranking algorithm is applied to nd length-3 tags and
their associated scores. The tags are sorted in a decreasing order of the tag scores, and placed in a set T .
A large score corresponds to high condence that a tag belongs to the peptide that generated the specic
spectrum.
The algorithm then uses the rst peptide tag in T to separate prospective whole sequences into smaller
pieces. If there are no unused tags in T , the whole algorithm stops after a candidate peptide ranking step;
else, the rst tag t in T is selected and deleted from T . Then the two mass regions separated by t are
calculated, stored in set Part, and compared to a predened threshold Thres. If any of the mass regions is
over Thres, further separation of the region is needed using another suitable tag t
0
in T ; else, all amino acid
compositions of all regions in Part are calculated. Here, any length-3 tag consists of four consecutive ions.
The mass values of the two end ions of t
0
should be in the interval of the mass region (over Thres) in order
to separate it.
After that, the algorithm calculates amino acid compositions (AACs) of each region in Part and builds
GMETs on these regions to nd partial peptide sequences. Finally, all suitable parts are assembled together
to form the nal peptide candidates, and a ranking scheme is applied to select and output the best ones.
These steps in the algorithm and the various variables appearing in Figure 4.1 are explained in detail in the
following subsections.
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Table 4.1: Ion types considered in ExD spectra
Ion Type Mass calculation from residues Mass calculation from other ions
c
P
(residue mass) + 18:0344 bm +mNH3
c  1. P(residue mass) + 17:0265 bm +mNH3  mH
z.
P
(residue mass) + 3:0156 ym  mNH3 +mH
z + 1
P
(residue mass) + 4:0156 ym  mNH3 + 2mH
w
P
(previous residue mass) + 73:0290 xprevious +mCO
b
P
(residue mass) + 1:0078 bm
y
P
(residue mass) + 19:0814 ym
4.2.1 Basic ion types considered in ExD spectra
Since ExD spectra have dominant ion types dierent from CID and HCD spectra, we rst investigate the
ion types considered for the proposed method. After study of the literature about the frequency of dierent
fragment ions [32,33,37,39,41,87], the ions listed in Table 5.2 were selected based on their frequency observed
in MS/MS spectra. Here, mNH3 , mH , mCO denote the mass of NH3, H, and the CO-group, respectively.P
(residue mass) is the mass sum of all amino acids from the end amino acid of a peptide sequence to the
amino acid at the current cleavage point. Similarly,
P
(previous residue mass) is the mass sum of all amino
acids from the end amino acid of a peptide sequence to one amino acid previous to the current cleavage
point. bm and ym are the masses of the b-ion and y-ion, respectively, at the current cleavage point. xprevious
is the mass of the x-ion at the cleavage point one position previous to the current one. In addition, the
complementary ion relationships in Equations (1)-(3) hold for the ions in Table 5.2.
bi + yN i = mp + 2mH ; (4.1)
ci + z
.
N i = mp + 3mH ; (4.2)
c  1.i + (z + 1)N i = mp + 3mH ; (4.3)
where mp is the mass of parent peptide P , N is peptide length, and i 2 f1; 2; : : : ; Ng. i is the ion mass of
the ith -ion, where  2 fc; c  1.; z.; z + 1; b; yg.
4.2.2 Charge determination of multi-charged fragment ions
Since ExD spectra resulting from multi-charged peptides are quite common, fragment ions in spectra are
often in multiple charge states. Fragment ions having dierent charges mixed together in a spectrum may
cause interpretation problems since the mass dierence calculation, a key measurement used in de novo
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peptide sequencing, is aected. Therefore, determination of fragment ion charges is quite useful in peptide
sequencing.
There are already a lot of methods developed for MS/MS spectrum charge deamination, and many
of them focus on the charge determination of precursor ions and utilize sophisticated machine learning
strategies [92, 93, 101, 102]. In this paper, we use a straightforward method to determine charges of all
fragment ions in a spectrum in order to reduce the complexity and reduce the computational time of the
proposed NovoExD.
Let the charge of a spectrum S from a peptide P be a non-negative integer n. The charge of a fragment
ion i, denoted i, in this spectrum is then a member of  = f+1;+2; : : : ; n   1g. Ions having charge n are
not considered since the majority of ions in S do not have such a charge value. To determine i without
knowing the peptide sequence, ion relationships are needed. Here, two dierent possible relationships are
considered. One is that the two ions are the same fragment ion with dierent charges, e.g. +1 and +2 of
the same c-ion. The other is that the two ions are complementary but with dierent charges, e.g. a +1 c-ion
and the complementary +2 z.-ion. These relationships are used to determine (part of) the ion charges in a
spectrum.
In a spectrum S with charge n, suppose fragment ion i has charge i 2 . Therefore, we have n   1
possibilities for the charge of an ion i 2 S. Then for S, we build n  1 scenarios assuming all ions in S are in
charge state i 2 , and calculate the associated n  1 spectra having all ions with charge state +1, denoted
as Sito1. The set of these n  1 spectra is denoted SA = fSito1 j i 2 g. Let j be an ion in Sito1. Then
8j 2 Sito1, we have j = 1, which means that all ions in Sito1 have charge values +1. The ion charges can
be inferred by considering the two relationships described in the previous paragraph. If two ions p 2 Spto1
and q 2 Sqto1 satisfy either of the relationships, where p; q 2 , then the associated ions of p and q in the
original spectrum S, denoted as ip and iq, are in charge state p and q, respectively. The detailed steps of
charge determination of multi-charged fragment ions are shown in the following. Here, the m=z value of an
ion i 2 S is denoted as (m=z)i.
1. For a spectrum S with charge n, calculate spectrum Sito1 consisting of only charge +1 ions. 8j 2 Sito1,
we have (m=z)j = i  (m=z)i   (i   1), 8i 2 S, and 8i 2 .
2. For ions p 2 Spto1 and q 2 Sqto1, calculateMdiff1 = j(m=z)p (m=z)qj, where p 6= q. IfMdiff1 < 1,
then the associated ions of p and q in S, denoted as ip and iq, are in charge state p and q, respectively.
1 is a small valued threshold. This calculation is between two of the n   1 spectra in SA indicating
the same ion with dierent charges.
3. For ions p 2 Spto1 and q 2 Sqto1, calculateMdiff2 = j(m=z)p+(m=z)q mp 3mH j, where p+q = n.
If Mdiff2 < 2, then the associated ions of p and q in S, denoted as ip and iq, are in charge state p
and q, respectively. 2 is a small valued threshold. This calculation can be on the same spectrum in
SA or two spectra in SA forming a complementary ion pair.
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4. Assign all identied i to i, and set j = 1 for the rest of the ions j 2 S; output results.
We give a simple example to show how the charges are determined. Assume all m=z values from an
experimental spectrum are stored in set S = f73; 109; 116; 130; 183; 217; 346; 365g. The parent mass is mp =
492, and the spectrum charge is +4. Here, we use integers to simplify the calculation and focus on the
principle of the algorithm.
Since the spectrum charge is +4, from the above algorithm three assumptions are made for the spectrum
that assume all ions are in charge states +1, +2, and +3, respectively. Then the three associated spectra
having all ions with charge state +1 are calculated as:
S1to1 = S = f73; 109; 116; 130; 183;217;346; 365g;
S2to1 = f145;217; 231; 259; 365; 433; 691; 729g;
S3to1 = f217; 325;346; 388; 547; 649; 1036; 1093g:
From the above sets, we rst nd identical elements which indicate the same fragment ion in dierent
charges. Number 217 (in boldface above) occurred 3 times and 346 occurred twice. From the name of the
set and the element positions, we infer that 73, 109 and 217 are the same ion in charge states +3, +2 and
+1, respectively; and 116 and 346 are the same ion in charge states +3 and +1, respectively. Subsequently,
we use complimentary ion relationships to infer ion charges of the ions in S. Since values 130 (underlined
above) in S1to1 and 365 in S2to1 satisfy such a relationship, we infer that 130 is in state +1 and 183 (the ion
at the same position of ion 365 in S) is in state +2. Finally, we label the only remaining ion 365 in S with
charge +1. After this process, every ion in S has a charge value.
4.2.3 GMET Model and de novo sequencing procedure
This GMET model used here is derived from [73]. The new graph type is of the form GMET=(V;E;),
where each peak (corresponding to a fragment ion) in an experimental spectrum is represented as a vertex
v 2 V and its m=z value is denoted as (m=z)v; each v has a charge value  2 , which is determined by the
charge determination process described above.
Five dierent types of edges (see Table 4.2) in E are considered in the GMET, and the detailed calculations
are described in the following. Here, mp denotes the mass of the peptide producing such an experimental
spectrum. A denotes the set of 20 amino acids, and ai 2 A is a certain amino acid. ai is also used to represent
its residue mass. mloss is dened to be the mass of some small molecules or groups lost from fragment ions,
which typically include H2O, NH3, CO- and NH- groups. 8u; v 2 V , if mu and mv denote their mass values,
then we have mu = ((m=z)v  u)  (u  1) and mv = ((m=z)v  v)  (v   1).  is a given threshold. When
the edge calculation in the GMET involves an amino acid mass, the tted amino acid labels the edge.
1. Type I edge, eIuv: A directed edge e
I
uv is drawn from u to v when j (mv  mu)  ai j .
2. Type II edge, eIIuv: An undirected edge e
II
uv is drawn between u and v when j mp+3mH (mv+mu) j .
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Table 4.2: Edge types in the GMET
Edge Relationship
Type I amino acid dierence
Type II u and v represent a complementary ion pair
Type III u and v represent a complementary ion pair with one amino acid overlap
Type IV u and v represent a complementary ion pair with one amino acid gap
Type V loss of a small molecule
3. Type III edge, eIIIuv : An undirected edge e
III
uv is drawn between u and v when j (mv +mu)   (mp +
3mH)  ai j .
4. Type IV edge, eIVuv : An undirected edge e
IV
uv is drawn between u and v when j mp + 3mH   (mv +
mu)  ai j .
5. Type V edge, eVuv: A directed edge e
V
uv is drawn from u to v when j (mv  mu) mloss j .
In the experiments described in this study,  = 0:01 Da. However, the threshold can also be set by users
according to their needs.
After the GMET is constructed, we denote G[V S] to be the graph induced by all vertices in the GMET
from a single cleavage site of the peptide whose sequence we are trying to infer (termed a basic structure).
From each G[V S] an amino acid can be inferred. From connected basic structures determined from the
GMET, continuous amino acids can be inferred. The detailed steps of inferring G[V S] (and amino acids)
from a GMET can be seen in [73]. Another graph, GMETAA, is then used to represent the relationship of
amino acid strings inferred from basic structures, in which the vertices VAA and edges EAA are dened as
below [73].
VAA: Each vertex represents an amino acid acquired from a basic structure of a GMET.
EAA: Two amino acids are connected by an undirect edge if they are inferred from two connecting basic
structures.
From a GMET, peptide sequences can be inferred by solving a path-nding problem in the simple graph
GMETAA. All paths are sorted in a decreasing order according to their length.
Since the GMET model considers multiple types of ions and dierent charges, the computational time and
the possibility of false positives are greater than those with less sophisticated methods. In order to address
this potential problem, more information from the spectra is integrated into the model. Peptide tags and
AAC information are incorporated in this method as they were in previous work [73], but with adjustment
for the ExD spectra. AAC, which consists of order-independent amino acid composition information of a
peptide, is helpful [95,96] in limiting the edges in a spectrum graph.
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In the previous method [73], a single tag with a length of three was used to separate the peptide sequence
into prex, tag and sux. Also an AAC in-house database was built containing all theoretically possible
AACs for any given mass of no more than 3000Da [73]. However, since there are many ExD spectra produced
from long peptides (typically  20), a single tag is not sucient to simplify the sequencing problem, and
the number of possible AACs increases dramatically with the increase of peptide length. Therefore, multiple
length-3 peptide tags are considered here to separate the whole peptide into suitably sized parts for sequencing
based on the GMET. The approach also yields a solution to the problem of increased numbers of possible
AACs.
The results in [73] have shown that the single tag strategy is no longer eective when the peptide length
is over 15. Based on the frequency of each amino acid occurring in a peptide [103], the average mass of a
peptide of length 15 can be determined to be approximately 1600Da. Therefore, the threshold (as shown in
Figure 4.1) to determine whether more tags are needed to separate a peptide is set to be Thres = 1600. With
this value of Thres, the AAC database can be limited to masses of no more than 1600Da, which reduces the
number of possible AACs considered in the GMET case dramatically.
An eective method named DirecTag [22] and the ranking criterion proposed in [73] are used here to
generate and rank tags. In the following, detailed steps of integrating peptide tags and AACs are shown.
1. Generate length-3 tags using DirecTag [22] and put them into a set T according to their ranking scores
in a decreasing order.
2. Select the rst tag t, and delete t from T .
3. Calculate the mass of its prex and sux separated by this tag, denoted as mpre and msuf . Store
the two mass intervals related to mpre and msuf into Part.
4. Go to Step 6 if mpre and msuf  Thres. Otherwise, nd the mass interval(s) larger than Thres,
denoted as [ms;me]; go to Step 5.
5. Search in T for the tag whose two end ions are in the interval of [ms;me]. If there is such a tag, denoted
as t
0
, go back to Step 3 using t
0
to separate [ms;me]; else, go to Step 6.
6. Find out all possible AACs of mass intervals in Part using the in-house AAC database.
7. Construct GMETs from both sides of the length-3 tag t. AAC information is applied to restrict the
choices of edges in such GMETs. Specically, only amino acids included in the AAC are considered
when forming edges. With each possible AAC, one GMET is constructed.
8. Combine all partial sequences to be whole candidate peptides, and put them into set Candidate.
9. Go back to Step 2 if T 6= ;, and use other tags in T ; else, rank sequences in Candidate and output
results.
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4.2.4 Candidate peptide ranking scheme
After all candidate peptides are put in set Candidate in the proposed algorithm, peptide ranking is the
last step. Apart from the mass dierence between parent peptide mass mp and the candidate peptide mass
(denoted as mp), unique features in ExD spectra are considered. According to the literature [33, 87], x-
ions (y-ion+CO) and z-ions (y-ion NH3, but not the z.-ion) are absent from ExD spectra. Therefore, if a
candidate peptide Pc is the correct peptide that produced a specic spectrum S, x-ions and z-ions calculated
from Pc should not be observed in S. That is to say, the fewer the number of x-ions and z-ions that are
calculated from a candidate peptide sequence based on S, the more likely it is the correct peptide.
Therefore, in the proposed ranking scheme each candidate peptide Pc can be represented as a vector
CP (mp; CZmatch), where CZmatch is the total number of x-ions and z-ions calculated from Pc observed in
S. The ranking scheme rst orders CP according to mp in a decreasing order, and then secondarily orders
CP according to CZmatch in a decreasing order. After this process, the candidate peptides are output with
their nal ranking.
4.3 Experiments and Results
4.3.1 Datasets
Three ExD spectral datasets were used to investigate the performance of NovoExD. Another newly developed
de novo peptide sequencing algorithm, pNovo+ [75], was used for comparison. It has been shown that
pNovo+ achieves superior sequencing results on various testing data compared to another successful de novo
sequencing software, PEAKS [62]. pNovo+ [75] can be used for HCD and (or) ExD spectra either alone or
together. Here, the ExD option in pNovo+ is used.
The rst dataset, SwedECD, contains ECD MS/MS spectra of doubly charged tryptic peptides [32]. The
average length of peptides in the database is 10.6 residues, and the average mass is 1196.6Da. The other two
datasets, SCX ETDFT no decon and SCX ETD decon, are from the same research paper [98]. The original
datasets contain various fragmentation MS/MS spectra including CID, HCD, and ETD spectra. The ETD
spectra were selected for the experiments here. The SCX ETD decon dataset contains ETD spectra with
deconvolution, and SCX ETDFT no decon dataset contains raw data without deconvolution of spectra. For
all spectra in these three datasets, a sequence is associated with each spectrum which is viewed as the correct
sequence of the peptide producing the spectrum. The number and charges of spectra in each dataset are
summarized in Table 6.2.
4.3.2 Parameters
There are several parameters needed for NovoExD, and the values applied in the experiments are listed
in Table 6.3. , 1, 2, and the number of output sequence are set according to our previous study and
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Table 4.3: Number of spectra and charges in each dataset used in the experiments
Dataset Number of spectra Charge of spectra
SwedECD 1414 +2
SCX ETDFT no decon 1298 +2, +3, +4, +5
SCX ETD decon 612 +2, +3, +4, +5, +6
Table 4.4: Parameters used in the experiments
Parameter Role in NovoExD Value
Threshold  GMET edge building 0.01Da
1 Charge determination 0.01Da
2 Charge determination 0.01Da
Thres Tag integration into GMET 1600Da
Number of tags Tag integration into GMET 10 per spectrum
Number of output sequences Candidate output 3 per spectrum
experiments [73, 100], and they can be changed by users for their needs. The value of Thres has been
introduced previously in detail. The number of tags is chosen to be 10 because that the tags ranked lower
than the top 10 tags are most likely to be wrong tags according to our previous study [73].
4.3.3 De novo peptide sequencing performance
All three datasets were used to investigate the performance of NovoExD and pNovo+. For each spectrum
in a dataset, the top three candidates produced by the two methods were output. If any one of the three
candidates from a spectrum was correct (the same as the sequence associated with this spectrum), it was
deemed that full length accuracy was achieved for this spectrum and for the given method. In order to
analyze the contribution of multi-tags and ion charges in NovoExD, sequencing results of using the GMET
model without multi-tags and ion charge information are also shown. Detailed comparison is presented in
Table 4.5. Since the SwedECD dataset consists of +2 spectra with average peptide length of 10.2 [32], most
of the fragment ions have charge +1 and a single tag is sucient for peptide sequencing. Therefore, we did
not use multi-tags and ion charges in the comparison and recorded \N/A" in the associated box in Table 4.5;
using these features is expected to yield results similar to those shown.
From Table 4.5 it is evident that the GMET model achieves better performance than pNovo+ on the
SwedECD dataset. Results for two datasets consisting of highly charged ( +3) spectra, SCX ETDFT no decon
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Table 4.5: Average full length peptide sequencing accuracy comparison
Dataset pNovo+
GMET without multi-tags Proposed
and ion charge information NovoExD
SwedECD 52.86% 72.25% N/A
SCX ETDFT no decon 63.02% 64.10% 85.83%
SCX ETD decon 64.62% 59.15% 88.70%
and SCX ETD decon, allow us to see the potential contribution of multi-tags and ion charges to peptide se-
quencing. The results in Table 4.5 illustrate that NovoExD obtains the highest full length accuracy among
all three methods, and the GMET without multi-tags and ion charges has performance similar to that of
pNovo+. Therefore, using these features dramatically improves the identication accuracy of highly charged
spectra ( +3). Specically, accuracy is improved 22.81% and 24.08% compared to pNovo+, and 21.73%
and 32.55% compared to the GMET model without multi-tags and ion charges.
Furthermore, we considered the relationship between the number of correctly identied peptides and pep-
tide length. Figures 4.2 and 4.3 summarize the results from comparing the output of NovoExD and pNovo+ on
two datasets, SCX ETDFT no decon and SCX ETD decon, respectively. These gures show that NovoExD
outperforms pNovo+ on almost every peptide length except lengths 15 and 19 on SCX ETDFT no decon,
and lengths 12 and 14 on the SCX ETD decon dataset, respectively. For length greater than 16, NovoExD
achieves almost perfect identication on the SCX ETD decon dataset, while pNovo+ has lower identication
accuracy. The lower accuracy of NovoExD for some lengths may be due to the threshold controlling whether
multi-tags are used. Some peptides may require multi-tags for better performance but do not achieve the
pre-dened threshold. In future study, we will explore more suitable thresholds for the use of multi-tags.
In addition, the relationship between the number of correctly identied peptides and spectrum charge was
examined. Tables 4.6 and 4.7 summarize the results of the comparison between NovoExD and pNovo+ on
the SCX ETDFT no decon and SCX ETD decon datasets, respectively. These tables show that NovoExD
outperforms pNovo+ under every spectrum charge. Thus for the two datasets consisting primarily of +3
and +4 charged spectra, NovoExD identies more peptides, which argues for the potential contribution of
using ion charge information for MS/MS peptide sequencing, especially with higher charged spectra. Since
the experiment here is limited, more investigation is needed to make a conclusive statement.
Finally, we examine the computational time of NovoExD. The algorithm was written using MATLAB
(2010b) and the program was run on a PC with a 3.07 GHz quad-core CPU and MS Windows 7 operating
system. The results for dierent datasets are shown in Table 4.8. Since a charge determination step is
part of NovoExD, in order to examine the eect of this step on the total running time, the time without
charge determination is also calculated for the SCX ETDFT no decon and SCX ETD decon datasets. The
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Figure 4.2: Comparison of the number of correctly identied peptides and peptide length between
NovoExD and pNovo+ using the SCX ETDFT no decon dataset.
SwedECD dataset contains only +2 charged spectra and all ions are assumed to be in charge state +1.
Therefore, there is no charge determination step needed for SwedECD dataset, and \N/A" is recorded in the
associated table cell. All run times (CPU times) in this table are given in seconds per spectrum.
From Table 4.8 one can see that the computational time varies among dierent datasets, but are all in an
acceptable time range; specically, the running time per spectrum is less than 2 seconds. Another interesting
result is that the running time without charge determination is far less than that with charge determination.
This step takes around two thirds of the total time. Therefore, in order to enhance the speed of NovoExD,
the focus should be on this most time-consuming step. If a faster and more ecient charge determination
method is developed, the whole running time can be reduced dramatically. Such investigation will be part
of our future study of this de novo peptide sequencing approach.
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Figure 4.3: Comparison of the number of correctly identied peptides and peptide length between
NovoExD and pNovo+ using the SCX ETD decon dataset.
Table 4.6: Comparison between the number of correctly identied peptides and spectrum charge
using the SCX ETDFT no decon dataset
Spectra charge pNovo+ identied NovoExD identied Total spectra
+3 488 583 682
+4 311 457 532
+5 1 9 9
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Table 4.7: Comparison between the number of correctly identied peptides and spectrum charge
using the SCX ETD decon dataset
Spectra charge pNovo+ identied NovoExD identied Total spectra
+3 181 204 247
+4 199 295 320
+5 5 28 28
+6 0 2 2
Table 4.8: Running time comparison on dierent datasets using NovoExD
Dataset SwedECD SCX ETDFT no decon SCX ETD decon
Number of Spectra 1414 1298 612
Time (sec.) per spectrum
0.41 2.09 0.53
for NovoExD
Time (sec.) per spectrum
N/A 0.45 0.18
without charge determination
4.4 Conclusions and future work
In this paper, a de novo peptide sequencing method for ExD spectra, NovoExD, has been proposed. It uses
a new spectrum graph model, considers multiple peptide tags to separate a peptide into small mass regions,
and integrates fragment ion charge and amino acid composition (AAC) information. Then, it combines small
regions to output complete sequences of candidate peptides. In addition, a charge determination step is used
to extract more information from highly charged ExD spectra.
Three datasets of ExD spectra were used to investigate the performance of NovoExD by comparing it
with another successful de novo peptide sequencing method, pNovo+, which has an option for ExD spectra.
Experimental results have shown that the improvements in terms of average full length peptide sequencing
accuracy are over 20% on all datasets when compared to pNovo+.
In future, we will improve NovoExD's accuracy, reduce its computational time, expand the evaluation
of NovoExD to more ExD datasets, and optimize the parameters in NovoExD. In addition, since a popular
approach to peptide sequencing is pairing dierent types of spectra from the same peptide to obtain more
information, we are planning to modify the model and apply it to the multiple spectra sequencing problem.
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Addendum
In the Subsection 4.2.2, when determining the ion charges, the equation in step 3 is from the previously
introduced equations 4.2 and 4.3.
Errata
1. In the second paragraph of Section 4.2, \The motivation of ..." should be changed to \The motivation
for ..."
2. In the forth paragraph of Section 4.2, \else," should be changed to\otherwise,".
3. In the fth paragraph of Section 4.2, \These steps in the algorithm and the various variables ..." should
be changed to\These steps in the algorithm and the dierent variables ...,".
4. In the Subsection 4.2.2, when determining the ion charges, the requirement of \where p + q = n" in
step 3 should be removed.
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Chapter 5
A framework of de novo peptide sequencing for mul-
tiple tandem mass spectra
Published as: Yan Yan, Anthony J. Kusalik and Fang-Xiang Wu. \A framework of de novo peptide
sequencing for multiple tandem mass spectra," IEEE Transactions on NanoBioscience, vol.14, no.4, pp.478-
484, June 2015.
In the previous chapter, a new de novo peptide sequencing method for ETD/ECD spectra, NovoExD,
is presented. NovoExD modies the model in NovoHCD and adds a charge determination step for multiple
charged ECD/ETD spectra. With the availability of various MS/MS spectra, the use of multiple spectra
from the same peptide for sequencing has become a new, popular research topic.
Multiple spectra peptide sequencing has the potential to extract more information from spectra than
single-spectrum based sequencing since information missed from one spectrum may be found in others.
This advantage thus gives multiple spectra sequencing the potential to signicantly increase the accuracy
and practicality of de novo sequencing. Currently, there are some methods designed for multiple spectra
sequencing, but the models may not be designed well enough to extract as much information as they could.
There is still room to develop advanced methods in this area. Therefore, the study presented in this chapter
focuses on multiple spectra sequencing.
This chapter presents a framework for multiple spectra sequencing and applies it to paired CID (or HCD)
and ECD (or ETD) spectra. The newly available MS/MS has two fragmentation modes installed, for example,
the CID and ETD modes. The two models are changed very quickly during the experiment so that the two
types of spectra output at the same time are viewed as the ones generated by the same peptide. These spectra
have dierent dominant fragment ions and are complementary to each other. They are the most widely used
pairs in MS/MS based peptide sequencing. The performance of the framework with application to this kind
of spectra pair is compared to another competing method named pNovo+. Experiential results on several
dataset pairs show that the proposed framework outperforms pNovo+ in terms of full length sequencing
accuracy on experimental datasets.
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Abstract
With tandem mass spectrometry (MS/MS), spectra can be generated by various fragmentation techniques
including collision-induced dissociation (CID), higher-energy collisional dissociation (HCD), electron capture
dissociation (ECD), electron transfer dissociation (ETD) and so on. At the same time, de novo sequencing
using multiple spectra from the same peptide generated by dierent fragmentation techniques is becoming
popular in proteomics studies. The focus of this study is the use of paired spectra from CID (or HCD)
and ECD (or ETD) fragmentation because of the complementarity between them. We present a de novo
peptide sequencing framework for multiple tandem mass spectra, and apply it to paired spectra sequencing
problem. The performance of the framework on paired spectra is compared to another successful method
named pNovo+. The results show that our proposed method outperforms pNovo+ in terms of full length
peptide sequencing accuracy on three pairs of experimental datasets, with the accuracy increasing up to
13.6% compared to pNovo+.
5.1 Introduction
When dealing with mass spectrometry-based peptide sequencing problems, there are three main kinds of
methods used: database searching, peptide tagging and de novo sequencing [17]. In database searching,
theoretical spectra are computed from an existing protein database and peptides are identied by matching
the theoretical spectra to experimental spectra [46]. The major disadvantage of database searching is that it
cannot identify new or unknown peptides. Peptide tagging [21,22] is usually used to reduce the search space
and time, and has the potential to improve de novo peptide sequencing. De novo sequencing has the ability
to identify new proteins, proteins resulting from mutations, proteins with unexpected modications and so
on. With the recent developments of high mass-accuracy MS/MS and alternative fragmentation techniques,
de novo sequencing has shown promising developments [48]. Therefore, this study focuses on MS/MS de
novo peptide sequencing.
Tandem mass spectrometry (MS/MS) is a commonly used technology for peptide sequencing. It measures
the mass-to-charge ratio (m=z) of the components in experimental compounds, and the data collected from
it is called a tandem mass spectrum (MS/MS spectrum) [48]. In MS/MS, peptide ions are fragmented into
dierent kinds of fragment ions, named a-, b-, c-, x-, y-, and z-ions. Dierent fragmentation techniques
used in MS/MS yield diering types of dominating fragment ions. Collision-induced dissociation (CID)
and higher-energy collisional dissociation (HCD) yield b-ions and y-ions as dominating ions [36]. Electron
capture dissociation (ECD) and electron transfer dissociation (ETD) preferentially produce variants of c-
ions and z-ions, and occasionally a-ions [31{33]. ETD [37] is a modication of the ECD technique [38]; it
produces high quality MS/MS spectra for multi-charged peptides, has no strong cleavage preferences, and
preserves labile post-translational modications (PTMs) [41]. These features yield spectra containing more
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useful information, which has the potential to give better performance when used in peptide sequencing.
In addition, all the fragment ions usually lose some small molecules such as H2O and NH3 during the
fragmentation.
With the appearance of alternative MS/MS spectra resulting from dierent fragmentation techniques,
novel computational methods have emerged to enhance de novo peptide sequencing performance. For ex-
ample, pNovo [72], which applies a spectrum graph model and combines immonium ions (IMs) and internal
fragment ion information from HCD spectra, has achieved superior peptide sequencing results. Its perfor-
mance on various testing data has been shown to be better than that of two previous algorithms, PEAKS [62]
and PepNovo [59]. We have previously proposed a de novo sequencing method for ECD and ETD spectra [17]
based on a new type of graph model, and the experiments on several MS/MS datasets showed that this method
achieved better peptide sequencing results, compared to another similar method [17] .
Apart from the algorithms based on single spectrum peptide sequencing, some researchers have tried to
use multiple spectra from the same peptide to infer peptide sequences [31, 75, 77, 79, 81]. Multiple spectra
peptide sequencing is promising because it has the potential to extract more information from spectra,
and signicantly increase the accuracy and practicality of de novo sequencing. The use of paired CID (or
HCD) and ECD (or ETD) spectra is the major focus of the current study because of the availability and
complementary properties of these spectra.
Savitski et al. [79] rst proposed a computational method that used two spectra from the same peptide
to infer peptide sequences. In their method, peaks appearing in both spectra representing the same partial
peptides were considered to be much more reliable than the rest of the peaks; they were used to create a
backbone of the sequence. The less reliable peaks were then used to ll the gaps in the sequence backbone
or extend the sequence until a full sequence was obtained. Another algorithm, CompNovo [77], employed
a divide-and-conquer approach combined with a mass decomposition algorithm, and extracted information
from CID and ETD fragmentation for peptide sequencing. This algorithm showed better peptide sequencing
results compared to the ones that only used CID spectra. In 2010, He and Ma [31] presented a new algorithm,
ADEPTS, to utilize multiple spectra for de novo sequencing. It was mainly focused on a new scoring function.
A new way of using intensity information was also included in this algorithm, which achieved better results
than programs like CompNovo. Most recently, Chi et al. proposed a de novo sequencing method named
pNovo+ [75] for HCD and ETD spectra pairs. It applied a spectrum graph model and combined dierent
fragment ion information from the two spectra, and showed superior results on various testing data.
In this paper, we present a new framework to deal with the multiple spectra sequencing problem, and
test its performance using spectra pairs from the same peptides. The proposed framework builds a modied
spectrum graph with multiple edge types (GMET) [73] by considering frequently observed fragment ions from
all spectra, and utilizes unique features from these spectra. Amino acid compositions and peptide tags from
both spectra are incorporated into the proposed method with consideration of the multiple spectra situation.
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5.2 Methods
In this section, the framework is proposed. It rst considers unique features from all experimental spectra
to generate a merged spectrum Sm, and then uses peptide tags to break a whole peptide sequence into
smaller regions. After that, the proposed method builds a GMET model for each region and uses amino acid
composition (AAC) information to limit the edge numbers in the GMET. It nally combines all smaller parts
to output complete sequences of candidate peptides. The whole framework is summarized in Figure 5.1.
5.2.1 Basic ion types considered in each spectrum
Previous study has determined the frequency of dierent fragment ions observed in dierent MS/MS spectra
[17, 32, 33, 41, 73]. The ions listed in Tables 6.1 and 5.2 are considered in the proposed method based on the
availability of spectra and observed frequency of dierent ions. At this time, CID, HCD, ECD, and ETD are
the most popular spectra used. If more kinds of spectra are available in future, new types of ions could be
incorporated into the framework.
In these tables, mH2O, mNH3 , mH , mCO denote the mass of H2O, NH3, H, and CO- groups, respectively.P
(residue mass) is the mass sum of all amino acids from an end amino acid of a peptide sequence to the
amino acid at the current cleavage site. Then,
P
(previous residue mass) equals
P
(residue mass) taking
o the mass of the amino acid at the current cleavage site. bm and ym are the masses of the b-ion and y-ion
at the current cleavage site, respectively. xprevious is the mass of the x-ion previous to the current one. An
ion annotated with \." is a radical fragment ion.
In Tables 6.1 and 5.2, the rst column presents the types of ions considered, and the second and third
columns give two kinds of mass calculation. The second column is the calculation based on previous residues,
which gives the relationship among cleavage sites. The third column is the calculation based on other types
of ions (specically, the b- and y- ions) at the same cleavage site.
Since ions lose small molecules and some fragmentation techniques yield special ions during MS/MS
experiments, the proposed method considers the following ions: basic types of ions in Tables 6.1 and 5.2,
small molecule loss (such as H2O and NH3) from all the basic types of ions, multi-charged (charges up to
n   1 for charge n precursor ion) basic ion types, and immonium ions (IMs) occurring frequently in HCD
spectra.
5.2.2 Spectra merging
The basic idea of spectra merging is to select signal ions from each spectrum to form a new spectrum, denoted
as Sm, which contains more useful information. Here, two kinds of relationships between ions are considered:
amino acid mass dierence and complementarity [90].
For amino acid dierence, with consideration of regular amino acid masses and loss of H2O and NH3,
all 2-tags (two amino acids long) in each spectrum are rst produced. Here, a length-2 tag consists of three
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Table 5.1: Ion types considered in CID/HCD spectra
Ion Type Mass calculation from residues Mass calculation from other ions
a
P
(residue mass)  26:9871 bm  mCO
b
P
(residue mass) + 1:0078 bm
x
P
(residue mass) + 44:9977 ym +mCO
y
P
(residue mass) + 19:0814 ym
Table 5.2: Ion types considered in ECD/ETD spectra
Ion Type Mass calculation from residues Mass calculation from other ions
c
P
(residue mass) + 18:0344 bm +mNH3
c  1. P(residue mass) + 17:0265 bm +mNH3  mH
z.
P
(residue mass) + 3:0156 ym  mNH3 +mH
z + 1
P
(residue mass) + 4:0156 ym  mNH3 + 2mH
w
P
(previous residue mass) + 73:0290 xprevious +mCO
b
P
(residue mass) + 1:0078 bm
y
P
(residue mass) + 19:0814 ym
ions (any two consecutive ion pairs having mass dierence close to an amino acid mass or an amino acid
mass plus/minues some small molecular) from an experimental spectrum. The three consecutive ions can be
denoted as u; v; t in spectrum S. Without loss of generality, we say the masses of u; v; t are in an increasing
order. Then, ion v is named as a \middle ion" and selected for the merged spectrum. The middle ion, which
has two other supporting ions from the spectrum, is more likely to be a signal ion rather than noise. For the
complementary relationship, all complementary ion pairs in each spectrum are selected.
For an experimental spectrum S and ions u; v; t 2 S, the charges of the ions are denoted u, v, and
t, and the m=z values of these ions in charge state +1 are denoted as u
+, v+, and t+. Since charges of
ions are unknown, in order to calculate all possible m=z values, we assume u, v, and t to be any positive
integers from +1 to (n  1), and calculate the associated n  1 spectra having all ions with charge state +1,
denoted as Sito1. Here n is the charge value of a given spectrum. There are already many algorithms for
MS/MS spectrum charge determination [92,93], and here we use a straightforward one similar to that in [17]
to simplify the calculation.
Additionally, we denote A as the set of 20 amino acids, and ai 2 A as a certain amino acid. ai is also
used to represent its residue mass. mloss is dened to be the mass of some small molecules or groups lost
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Table 5.3: Relationships and ions selected in spectra merging.
Relationship Ions selected
j (v+   u+)  ai +  j  v
and j (t+   v+)  aj    j  (middle ion)
j mp + 2mH   (v+ + u+)  j  v and u if u; v 2 Sc
j mp + 3mH   (v+ + u+)  j  v and u if u; v 2 Se
from fragment ions, which includes H2O and NH3. Relationships and ions in Table 5.3 are then utilized.
In the table, ai; aj 2 A;  can be 0 or mloss (considering the loss of small molecules of fragment ions);  is
a given threshold; and mp is the parent peptide mass. Finally, Sm consists of all middle ions in 2-tags and
complementary ion pairs for a given pair of MS/MS spectra. All ions in Sm come with charge values from
this step.
Here, we give a simple example to show how the merging step works. Assume the m=z values of two
experimental spectra are Sc = f130; 199; 277; 346g (represent a CID spectrum) and Se = f132; 182; 234g
(represent a ETD spectrum), respectively. The parent mass is mp = 492. Sc is in charge state +2 and Se is
in charge state +3. The lost small molecule is H2O, and then mloss = 18. Here, we use integers to simplify
the calculation and focus on the principles of the method.
Converting all ions to charge state +1, three associated spectra are generated:
Sc1to1 = f130;199; 277; 346g;
Se1to1 = f132; 182; 234g;
Se2to1 = f263; 363; 467g:
We rst deal with Sc1to1. From the calculations in Table 5.3, we get that values 130, 199, and 346 satisfy
j (199  130)  aS +18 j= 0 and j (346  199)  aE   18 j= 0, where aS = 87 and aE = 129 are the masses of
serine and glutamine, respectively. Then we infer that the ion having m=z value of 199 (in boldface above)
is a fragment ion having lost a molecular of water, and it is added to the merged spectrum Sm. In addition,
we get that values 199 and 277 (underlined above) satisfy j 492 + 2mH   (199 + 277)   18 j= 0. Then we
infer that these two ions are complimentary ions, and the ion having m=z value of 277 is a regular ion. Both
ions are in charge state +1.
We now deal with Se1to1 and S
e
2to1. Values 132 and 363 (underlined above) satisfy j 492 + 3mH   (132 +
363) j= 0. Then we infer that these two ions are complimentary ions, and the ion having m=z value of
182 is in charge state +2 (the ion at the same position as ion 363 in Se1to1). Therefore, the nal Sm =
f132; 182; 199; 277g, and their charges are known from the above steps.
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5.2.3 Parent mass correction
In this problem there are multiple MS/MS spectra and each comes with a parent peptide mass. These
masses are probably dierent, though they should be close. Therefore, before de novo sequencing, parent
mass correction is needed. Here, complementary ion pairs are used to nd the optimal parent mass in a given
region. The model hypothesis is that the real parent mass has the minimal mass dierence to complementary
ion pair masses.
Denote complementary ion pairs in Sm as CIP = f(Ij ; Icj ) j j = 1; 2;    kg, where Ij ; Icj 2 Sm are
complementary ions, and k is the total number of complementary ion pairs. We nd the optimal parent mass
Pmass by solving the following optimization problem
minkj=1 j (Ij + Icj )  Pmass j2
s:t: Pinf  Pmass  P sup (5.1)
Here, Pinf and P
sup are the inmum and supremum of Pmass, respectively. In practice, users could set the
two masses as the maximum and minimum masses of these spectra, or other suitable values as needed. Since
the above problem is a convex optimization problem with one unknown variable Pmass, the minimal value of
Pmass can be uniquely determined [104].
5.2.4 De novo sequencing model
The sequencing model proposed here is derived from [17] and [73] with modications designed for the multiple
spectra sequencing problem. It uses a new type of spectrum graph with multiple edge types (GMET),
considers multiple peptide tags to separate a peptide into small mass regions, and integrates fragment ions in
the merged spectrum Sm and amino acid composition (AAC) information. For each mass region combination
(see Figure 5.1, set Part) separated by several tags, a GMET is built.
In graph GMET = (V;E;) each peak (corresponding to a fragment ion) in the experimental spectrum
is represented as a vertex v 2 V and its m=z value is denoted as (m=z)v. Each v has a charge value  2 ,
which is determined by the previous merging step. The default value of  is +1. 8u; v 2 V , let mu and mv
denote their mass values, then we have mu = ((m=z)u  u)  (u   1) and mv = ((m=z)v  v)  (v   1).
Five dierent types of edge in E are considered in the GMET, and the detailed calculations can be found
in [17].
A major dierence in this GMET compared to the one in [17] is that it considers all ion types in Tables
6.1 and 5.2 when sequencing using Sm. Another dierence in the sequencing model is the use of peptide tags.
Since there are multiple experimental spectra and one merged spectrum Sm, instead of generating tags from
Sm, the model uses experimental spectra separately to produce multiple peptide tag sets (by the DirecTag
algorithm [22]), and uses the ranking scheme in [73] to sort them. The reason for this is that DirecTag is
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designed for a single MS/MS spectrum, not a merged spectrum, and the mixed types of ions in Sm are a
source of diculty for DirecTag.
With more types of ions considered, the computational time and the possibility of false positives may be
increased in the model. As a solution, AAC, which consists of order-independent amino acid composition
information of a peptide [95], is incorporated into the model to limit the edges in a GMET. For a given mass
region, possible AACs are generated for such specic mass; and only amino acids in an AAC will be used
as edge choices in a GMET. From the GMET model, the proposed method infers partial peptide sequences
on each segment, and assembles them into nal candidate sequences. The steps of sequencing by the GMET
model with integrated peptide tags and AAC are shown in Figure 5.1.
5.2.5 Candidate peptide ranking
When all candidate peptides have been produced, the last step is to rank these candidates and determine the
most likely correct ones. A theoretical spectrum generated from the correct sequence is expected to have the
best match to the experimental spectrum. Therefore, we use this feature as well as ion intensity to design a
candidate ranking scheme. The detailed steps are shown below.
1. For a candidate peptide sequence Pcan 2 Candidate, generate a theoretical spectrum for each ex-
perimental spectrum. Ion types considered are the ones in this specic spectrum that were used for
generating spectrum Sm. All ion intensities in the theoretical spectra are dened as a constant value.
2. Compare the theoretical spectra with experimental spectra, and select matching ions from each pair of
spectra with a mass dierence less than the predened threshold r.
3. Sum the intensity values of matching ions in the experimental spectra to be the nal ranking score of
Pcan.
After this process, each candidate peptide will be assigned a ranking score. The higher the score, the more
likely it is that this sequence is the correct one generating the input experimental spectra. In the proposed
method, for a set of input spectra, the top 3 highest scoring candidates along with their ranking scores are
output as results.
5.3 Experiments and Results
We applied the framework to MS/MS spectra pairs to evaluate its performance. Here, three pairs of datasets
were used. Another newly developed de novo peptide sequencing algorithm for paired spectra, pNovo+ [75],
was used for comparison. pNovo+ [75] can be used for HCD and (or) ETD/ECD spectra either alone or
together. It has been shown that pNovo+ achieves superior sequencing results for paired spectra sequencing
on various testing data compared to other methods [75]. In addition, our previously proposed methods for
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Table 5.4: Number of spectra and charges in each dataset used in the experiments
Dataset
Number of Charge of Number of
total spectra spectra selected spectra
SwedECD 11491
+2 3119
SwedHCD 10878
SCX HCD decon 1952
+2 to +6 402
SCX ETD decon 612
SCX HCD no decon 2557
+2 to +5 753
SCX ETD no decon 1298
HCD and ECD/ETD spectra [17,73] were included for further comparison. The detailed experimental process
and results comparison are presented below.
5.3.1 Datasets
There are three pairs of HCD and ECD/ETD spectral datasets used in the experiments. The rst pair
of datasets are the SwedHCD and SwedECD datasets, which contain doubly-charged MS/MS spectra of
unique peptides [32, 97]. The other two pairs of datasets, SCX HCD decon and SCX ETD decon, plus
SCX HCD no decon and SCX ETD no decon, are from the same research paper [98]. The latter dataset pair
(labeled with \ no decon") contains raw data without deconvolution of spectra while the other pair contains
spectra with deconvolution. The original datasets contain various fragmentation MS/MS spectra including
CID, HCD, and ETD spectra. The HCD and ETD spectra were selected for the experiments here. The
reason that HCD instead of CID spectra were selected is that, typically, HCD spectra are more informative
and contain special ions (immonium ions). Each spectrum in the above datasets has a correct sequence
associated with it. In order to conduct our experiments, we selected spectra pairs having the same peptide
sequence from the paired datasets. The number of spectra, the charges of spectra, and the number of selected
pairs of spectra in the datasets are summarized in Table 6.2.
5.3.2 De novo peptide sequencing performance
Before investigating the performance of the proposed method, we rst conducted peptide sequencing based
on a single spectrum. There was no need to test the proposed method on the spectra pairs for which single
spectrum methods output identical and correct results. Such spectra are of sucient quality that any one of
the two produced a satisfying result. The remaining paired spectra constitute a much more rigorous test and
those were used in testing the proposed method and comparing it against the other sequencing algorithms.
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Table 5.5: Full length peptide sequencing accuracy based on a single spectrum for dierent datasets.
Dataset Method Accuracy
Number of
correctly identied
spectra by
both methods
SwedHCD NovoHCD 95.80% (2988)
2516
SwedECD NovoGMET 86.47% (2697)
SCX HCD decon NovoHCD 80.59% (324)
241
SCX ETD decon NovoGMET 87.31% (351)
SCX HCD no decon NovoHCD 84.99% (640)
504
SCX ETD no decon NovoGMET 85.66% (645)
Since our previously proposed single spectrum sequencing methods NovoHCD [73] and NovoGMET [17]
both showed superior results on various datasets compared to pNovo and pNovo+, sequencing based on these
two methods was conducted. For each spectrum, the top three candidates output were considered. If any
one of the three candidates interpreted from a spectrum was correct, we say that the method achieved a
full length accuracy for the given spectrum. The results for full length accuracy based on a single spectrum
are presented in Table 5.5. In this table, the numbers in brackets are the counts of correctly identied
spectra. The last column of this table is the number of correctly identied spectra by both methods for a
given dataset pair. For instance, in datasets SwedHCD and SwedECD, single spectrum sequencing methods
NovoHCD and NovoGMET identied 2988 and 2697 spectra, respectively. Among those spectra, 2516 spectra
were correctly identied by both methods, which means that NovoHCD and NovoGMET output identical
and correct sequencing results for these spectra.
Then, we ltered out those spectra pairs that both NovoHCD and NovoGMET have correctly identied,
and used the remaining spectrum pairs to compare the performance of the proposed method and pNovo+. The
total number of spectrum pairs selected from the three dataset pairs were 3119, 402 and 753, respectively.
The numbers of spectrum pairs correctly identied by the two single spectrum sequencing methods were
2516, 241 and 504, respectively. Then the remaining spectrum pairs for the proposed method versus pNovo+
performance comparison were 603, 161 and 249, respectively. These numbers are shown in Table 5.6 together
with the full length peptide sequencing results for the proposed method and pNovo+.
From Table 5.6 one can see that for all datasets, the proposed method achieved higher full length accuracy
than pNovo+, and the improvement is up to 13.6%. The improvement varies indicating property dierences
among these datasets. The rst dataset pair produced the highest accuracy, and this may be partly because
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Table 5.6: Full length peptide sequencing accuracy comparison among dierent datasets.
Dataset
Number of accuracy accuracy of the
spectra pairs of pNovo+ proposed method
SwedHCD 603 81.76% 95.36%
and SwedECD (=3119-2516) (493) (575)
SCX HCD decon 161 77.02% 83.85%
and SCX ETD decon (=402-241) (124) (135)
SCX HCD no decon 249 84.74% 94.78%
and SCX ETD no decon (=753-504) (211) (236)
of the low spectrum charge (+2) in this pair. Low spectrum charge results in the fragment ions in such
spectra having lower charges and less complexity than the ions in higher charged spectra. This makes the
spectra simpler and easier for the methods to process and interpret correctly. Similarly, we see that the
second dataset pair contains the largest spectrum charge range (from +2 to +6), and both pNovo+ and the
proposed method achieved their lowest sequencing accuracy on it.
Furthermore, we considered the relationship between the number of correctly identied peptides and
peptide length. Comparison between the proposed method and pNovo+ on SwedHCD and SwedECD datasets
is shown in Figure 5.2. The reason for showing this pair is because it has the largest number of spectra among
all datasets, and is expected to provide the most comprehensive comparison.
Figure 5.2 shows that the proposed method outperforms pNovo+ on every peptide length in this pair of
datasets. The sequencing results of the two methods are similar when peptide length is small { for example,
less than 9 { and both methods achieve almost perfect results. However, with increased of peptide length,
the proposed method shows signicantly better results than pNovo+. One can see that when the peptide
length is 21, pNovo+ identies no correct results while the proposed method identied all spectra in this
pair of datasets. Another interesting result from the Figure 5.2 is that when the peptide length is 22, both
methods identify all spectra. The varied performance of pNovo+ may indicate the complexity of the spectra
generated by long peptides. However, since the number of such spectra in this pair of datasets is small,
further experiments and analysis of spectral properties are needed to get a rm conclusion.
The remaining two dataset pairs in the experiments contain multiple charged spectra. Therefore, they can
be used to examine the relationship between the number of correctly identied peptides and peptide charge.
Since dataset pair SCX HCD no decon and SCX ETD no decon contains more spectrum pairs, this dataset
pair is used. Figure 5.3 summarizes the comparison between the proposed method and pNovo+. Since two
spectra in a pair may have dierent charge values, the higher charge is used as the spectrum charge of this
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Figure 5.2: Comparison of the number of correctly identied peptides verses peptide length for the
proposed method and pNovo+ on the SwedHCD and SwedECD dataset pair.
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Figure 5.3: Comparison of the number of correctly identied peptides verses peptide charges for the
proposed method and pNovo+ on the SCX HCD no decon and SCX ETD no decon dataset pair.
pair in this gure.
Figure 5.3 shows that NovoGMET outperforms pNovo+ for almost all spectra. For the two datasets
consisting primarily of +3 and +4 charged spectra, the proposed method identies more peptides than
pNovo+; but on charges +5, the proposed method shows a decrease. The reason for this might be that the
complexity of charge +5 spectra causes some problems for the proposed method. However, more experiments
are needed to come up with a rm conclusion about this issue.
5.4 Conclusions and future work
In this paper, a new solution to the de novo peptide sequencing problem for multiple spectra has been pro-
posed. The proposed framework denes a way to merge multiple experimental spectra, uses a new spectrum
graph model (GMET) and dierent fragment ion types occurring in them, considers length-three peptide tags
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to separate a peptide into small regions, and integrates amino acid composition (AAC) information into the
graph model. In addition, the proposed method includes a parent peptide correction step, which is essential
in solving the multiple spectra sequencing problem.
The proposed framework is applied to peptide sequencing using a pair of spectra from the same peptide.
Three pairs of spectral datasets were used to investigate and compare the performance of the proposed
method and another successful de novo peptide sequencing method, pNovo+. Experimental results have
showed that the proposed method outperforms pNovo+ in terms of full length peptide sequencing accuracy,
with the accuracy increasing by up to 13.6%. For long peptides (more than 20) and highly-charged (+5)
peptides, both methods show decreases to varying degrees, hence they are still challenging problems in de
novo peptide sequencing. The proposed method, which breaks peptides into smaller parts, and integrates
AACs information and GMET model, provides a promising solution to solve these problems.
In future, we will evaluate the proposed method on more MS/MS datasets and compare it to other
available paired spectra sequencing methods. In addition, we are also planning to apply the framework to
more spectra { for example, CID, HCD, and ETD triplets { for de novo peptide sequencing.
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Erratum
In Figure 5.1, the second step should be \Use Sall to generate merged spectrum Sm, and conduct mass
correction".
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Chapter 6
De novo peptide sequencing using CID and HCD spec-
tra pairs
Prepared as: Yan Yan, Anthony J. Kusalik and Fang-Xiang Wu. \De novo peptide sequencing using CID
and HCD spectra pairs (unpublished)". This is a manuscript resubmitted to Proteomics after a revision in
June, 2015.
In the previous chapter, a framework of de novo peptide sequencing for multiple tandem mass spectra is
presented. It is then applied to paired CID (or HCD) and ECD (or ETD) spectra. The reason for choosing
this kind of spectra pair is the complementary features of them. With the availability of various kinds of
spectra, other types of spectra combinations could be used for peptide sequencing as well. For example, CID
and HCD spectra.
CID and HCD spectra have similar dominant ions. Specically, they both produce b-ions and y-ions
primarily. Additionally, HCD spectra usually have more abundant ions in the low mass region (typically
below 200 Da) than CID spectra; to be specic, they produce immonium ions (IMs) and internal ions. The
pairing of these spectra has the potential to identify dominant fragment ions with high condence, and the
use of spectrum specic ions can help with the sequencing, too. However, less attention has been paid to
CID and HCD spectra pairs currently. Therefore, the study presented in this chapter is to develop a new
method specically for this kind of spectra pair.
In this chapter, CID and HCD spectra are studied and a new sequencing method designed for them
is proposed. The proposed method includes a merging criteria for CID and HCD spectra and a parent
mass correction step. Experimental results on several MS/MS spectral datasets show that the proposed
method outperforms other single-spectrum-based methods and identies some new peptides that other single-
spectrum-based methods cannot identify.
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Abstract
In tandem mass spectrometry (MS/MS) there are several dierent fragmentation techniques possible in-
cluding collision-induced dissociation (CID), higher-energy collisional dissociation (HCD), electron capture
dissociation (ECD), and electron transfer dissociation (ETD). When using pairs of spectra for de novo peptide
sequencing, the most popular methods are designed for CID (or HCD) and ECD (or ETD) spectra because of
the complementarity between them. Less attention has been paid to the use of CID and HCD spectra pairs.
In this study, a new de novo peptide sequencing method is proposed for these spectra pairs. This method
includes a CID and HCD spectra merging criterion and a parent mass correction step, and modies our
previously proposed algorithm for sequencing the merged spectra. Two pairs of spectral datasets were used
to investigate and compare the performance of the proposed method with two other methods designed for
single spectrum (HCD or CID) sequencing. Experimental results showed that full length peptide sequencing
accuracy increased dramatically by using spectra pairs in the proposed method, with the highest accuracy
reaching 81.31%.
6.1 Introduction
Tandem mass spectrometry (MS/MS) is a widely used technology for peptide sequencing. MS/MS measures
the mass-to-charge ratio (m=z) of the fragment ions of peptides in compounds, and outputs tandem mass
spectra (MS/MS spectra) [48] containing m=z values and intensities of ions. In MS/MS, the most common
fragment ions are named a-, b-, c-, x-, y-, and z-ions according to the cleavage sites on a peptide backbone
that gives rise to them. Dierent fragmentation techniques used in MS/MS yield diering dominant fragment
ions. Collision-induced dissociation (CID) is the traditional fragmentation technique used in MS/MS and it
yields b-ions and y-ions as dominant ions. With the development of new fragmentation techniques, alternative
MS/MS spectra appeared in recent years. Higher-energy collisional dissociation (HCD) spectra have similar
dominant ions as CID spectra but with more abundant ions in the low mass region (typically below 200
Dalton); specically, immonium ions (IMs) and internal ions [36]. Electron capture dissociation (ECD) and
electron transfer dissociation (ETD) preferentially produce variants of c-ions and z-ions, and occasionally
a-ions [31{33]. In addition, all the fragment ions usually lose small molecules such as H2O and NH3 in the
fragmentation process.
Database searching, peptide tagging and de novo sequencing [17] are the most popular methods for
peptide sequencing using MS/MS spectra. The success of database searching typically relies on the candidate
peptides generated from an existing protein database and the eectiveness of the scoring scheme measuring
the similarity between theoretical spectra and experimental spectra [46]. De novo sequencing does not need
a prior database, and thus has the ability to identify proteins that are not included in current databases,
proteins resulting from mutations, proteins with unexpected modications and so on. The main challenge
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in de novo sequencing is to extract enough information from experimental spectra (usually accounting for
noise and missing data) to infer the correct peptide sequences. Peptide tagging [21, 22] is usually used with
database searching or de novo sequencing to reduce the scale of computation. With the recent development
of high mass accuracy MS/MS and alternative fragmentation techniques, de novo sequencing has shown
promising developments because of the availability of dierent types of spectra with more information in
them [48]. Therefore, this study focuses on MS/MS de novo peptide sequencing.
With the appearance of alternative MS/MS spectra resulting from dierent fragmentation techniques,
novel computational methods have emerged to enhance de novo peptide sequencing performance. For ex-
ample, pNovo [72], which employs a spectrum graph model and combines immonium ions (IM) and internal
fragment ion information from HCD spectra, has achieved superior peptide sequencing results. Apart from
the algorithms based on single spectrum peptide sequencing, many researchers have tried to use multiple
spectra from the same peptide to infer peptide sequences [31,75,77,79]. Multiple spectra peptide sequencing
extracts information from all spectra, and thus has the potential to increase the accuracy and practicality
of de novo sequencing [105]. The use of a pair of spectra from CID (or HCD) and ECD (or ETD) fragmen-
tation is the major focus of active study because of the complementary properties of these spectra pairs.
Some successful methods include CompNovo [77], ADEPTS [31], pNovo+ [75], and NovoPair [81]. Recently,
a universal de novo sequencing tool named UniNovo has been proposed [84]. It is based on a spectrum
graph model, can be used for various types of spectra, and achieves satisfying sequencing results on various
experiential datasets. At this moment, there is still a lack of methods particularly designed for spectra with
similar dominant ions, for instance, CID and HCD spectra pairs.
A straightforward way of utilizing CID and HCD spectra pairs for sequencing is to combine the two spectra
into a single one. However, more noise may be introduced by this method. Ion redundancy is another problem
since the spectra have the same (or similar) dominant fragment ions. Therefore, in order to better use the
information from these spectra, a new de novo peptide sequencing method is needed. Here, such a method
for CID and HCD spectra pairs is proposed. The proposed method includes a merging criterion for CID and
HCD spectra and a parent mass correction step that considers the unique features of this spectra pair, and
it contains a modication of our previously proposed algorithm for HCD spectrum [73] to perform de novo
sequencing on merged spectra. Peptide tags and amino acid compositions are used to reduce the scale of
computation in the proposed method. The proposed method is then implemented as MATLAB code.
The reminder of the paper is organized as follows: Section 2 presents the design of the proposed method,
Section 3 shows the experimental results and performance analysis, and nally Section 4 concludes the paper
and gives some directions for future work.
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6.2 Methods overview
In this section, the proposed method is briey introduced. The detailed methodology is in the Additional
Files section. The proposed method rst considers unique features from experimental spectra to generate
a merged spectrum Sm, and then uses fragment ions in the experimental spectra to conduct a parent mass
correction. After that, it uses peptide tags from Sm to break a whole peptide sequence into smaller regions.
Assume that Thres is the threshold controlling the size of the regions. If the mass range of a region is larger
than Thres, more tags are used to further decompose it until all regions are no larger than the predened
threshold. A previously proposed method for HCD spectra, NovoHCD [73], with modications is then applied
for sequencing using Sm. Detailed information about NovoHCD and its modication is in the Additional
Files section.
Another important aspect of the method's design is the types of fragment ions considered. Some common
fragment ions observed in CID and HCD spectra have been introduced in the previous section. Based on
the literature [17,32,33,41,73], ions listed in Table 6.1 are considered in the proposed method. In Table 6.1,
mCO is the mass of a molecule of CO.
P
(residue mass) is the mass sum of all amino acids from an end
amino acid of a peptide sequence to the amino acid at the current cleavage site. bm and ym are the masses of
the b-ion and y-ion at the current cleavage site, respectively. In Table 6.1, the rst column lists the type of
ion, and the second and third columns give two ways to calculate the mass of that type of ion. The second
column is the calculation based on previous residues, which gives the relationship of consecutive cleavage
sites on a peptide backbone. The third column is the calculation based on other ions (either b- or y- ions) at
the same cleavage site.
Table 6.1: Ion types considered in CID and HCD spectra
Ion Type Mass calculation from residues Mass calculation from other ions
a
P
(residue mass)  26:9871 bm  mCO
b
P
(residue mass) + 1:0078 bm
x
P
(residue mass) + 44:9977 ym +mCO
y
P
(residue mass) + 19:0814 ym
In addition, two other ions frequently observed in HCD spectra, immonium ions (IM) and internal frag-
ment ions, are considered. Internal b- and y- ion with length up to two amino acids are also considered.
They provide supplemental information for peptide sequencing as well as candidate ranking. Other useful
ions include fragment ions at the end of the peptide backbone like b1-ions and y1-ions, and a2=b2-ion pairs.
Furthermore, the complementary ion relationships in Equations (1)-(2) hold for ions in Table 6.1. In the
equations, mp is the mass of the parent peptide P , N is the peptide length, and i 2 f1; 2; : : : ; Ng.
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jmp + 2mH   (bi + yN i)j = 0 (6.1)
jmp + 2mH   (ai + xN i)j = 0 (6.2)
In the proposed method, all ions introduced above and small molecule loss (such as H2O and NH3) are
considered.
After determining the types of ions, the next step in the proposed method is to merge the paired CID and
HCD spectra into one spectrum. This is done using an iterative selection process. An initial set S0m is created
by collecting three types of ions: ions from both spectra with very small mass dierence, complementary
ion pairs from both spectra, and all IMs from the HCD spectrum. The mass dierence threshold for the
selection is denoted as 1. Any ion pair with very small mass dierence is transformed into a single ion in
the merged spectrum, with its m=z value being the average and intensity being the sum of the contributing
values, respectively. From S0m, successive iterative steps create a series of sets S
i
m, where i 2 [1; t]. To form
Sim , the iterative step selects ions from the remainder of the original spectra pair where the mass dierence
between the candidate ion and an ion in the previously generated set Si 1m is close to one amino acid (mass
dierence threshold 1). In addition, ion intensity information is considered. To be specic, if Imax is the
highest intensity value of ions in the spectra pair, then a candidate ion must have intensity value greater than
or equal to Imax2 . The reason of having Imax divided by 2 is from past experience, and the users can also
choose other suitable values. With larger values, the threshold becomes lower, and more ions including more
noise could be selected; with smaller values, the threshold becomes higher, and more noise could be ltered
out but some fragment ions may be lost, too. Ions meeting these criteria are added into the set Sim. The
iterative process terminates when no more ions can be selected. As a post-processing step, the remaining
ions in the spectra pair are re-examined. Any ion having intensity larger than the two ions on either side of
it is added to Si+1m . All selected ions in S
i
m from the above steps comprise the nal merged spectrum Sm.
Since two MS/MS spectra are used in the proposed method, there are two parent masses. The two masses
may be dierent, though they should be close. Thus, a parent mass correction is performed to determine a
single, unique mass value for the subsequent peptide sequencing. The details are presented in the Additional
Files section.
The proposed method also modies our previous proposed de novo peptide sequencing method for HCD
spectra. A major dierence is the inclusion of a spectra merging step. Here, we give a simple example to
show how the merging step works. Assume the m=z value, intensity pairs of two experimental spectra are
Sc = f(130,0.3); (182; 0:2); (199; 0:5); (346,0.7); (433,0.5); (466; 0:3)g (representing a CID spectrum) and
Sh = f(60,0.2); (130,0.5); (217,0.4); (231; 0:3); (493,0.5)g (representing a HCD spectrum), respectively.
The meaning of dierent fonts and underlining will be explained in the following content. Spectra Sc and
Sh are also shown in Figures 6.1 and 6.2. The parent mass for both spectra is mp = 648. Mass dierence
threshold 1 = 0.01Da. In order to simplify the calculation and focus on the principles of the method, we use
integer m=z values, assume that all ions are in charge state +1, and do not consider loss of small molecules.
74
Figure 6.1: The spectrum of Sc
All intensity values in Sc and Sh are in the range of [0,1] to simplify the calculation.
We rst nd ions forming S0m. As shown on spectrum Sc and Sh Figure 6.3 (blue double arrow with
label \Same M=Z" on it), since both spectra have m=z value 130, it is added into S0m. Its intensity is the
sum of two ions' intensity values. During the check for IMs in the HCD spectrum, the rst ion (m=z=60) is
selected as it indicates glutamic acid (mass dierence is within the threshold 1). Then we use parent mass
to nd out complementary ions. Since j 648 + 2mH   (217 + 433) j= 0, ions having mass values as 217 and
433 are complementary ions. Therefore, S0m = f(60; 0:2); (130; 0:8); (217; 0:4); (433; 0:5)g whose elements are
highlighted in boldface above and shown in Figure 6.3 as spectrum S0m.
Having S0m, we conduct the iteration by using amino acid masses and ion intensities. First we consider
amino acid mass dierences. Pair (130,0.8) is in S0m while the pair (231,0.3) is not yet in the set. We observe
that j (231   130)   aT j 1 where aT is the mass of threonine (referenced ions are highlighted by a black
arrow in Figure 6.3). Hence the ion with m=z value of 231 could potentially be added to S1m. However, its
intensity does not satisfy the intensity criterion. Pair (217,0.4) is in S0m while the pair (346,0.7) is not. We
observe that j (346  217)  aE j 1 where aE is the mass of glutamic acid (referenced ions are highlighted
by a black dashed arrow in Figure 6.3). Further the intensity of (346,0.7) satises the intensity criterion.
Therefore (346,0.7) is added to S1m. This is denoted by (346,0.7) appearing in italic in a preceding paragraph.
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Figure 6.2: The spectrum of Sh
Since there are no more ions in the remaining spectra satisfying the amino acid dierence relationship with
the ions in S0m, S
1
m = (346; 0:7).
Similarly, pair (346,0.7) is in S1m while the pair (493,0.5) has not been added yet. We observe that
j (493   346)   aF j 1 and the intensity of (493,0.5) satises the intensity criterion. (493,0.5) is added
to S2m (referenced ions are highlighted by a black dashed line in Figure 6.3). This is denoted by (493,0.5)
appearing in italic in a preceding paragraph. Since there are no more ions in the remaining spectra satisfying
the amino acid dierence relationship with the ions in S1m, S
2
m = f(493; 0:5)g. At this time, as there are no
more ions that can be selected by using amino acid masses, the iteration stops. All ions selected from the
iteration are added together and shown as spectrum S0 [ S1 [ S2 in Figure 6.3.
Finally, by checking the intensities of the remaining ions in both spectra, ion (199,0.5) is selected.
Sm3 = f(199; 0:5)g. In this example, ions (182,0.2), (199,0.5), and (466,0.3) (underlined above and shown
in the spectrum Sleftc in Figure 6.3) are left from the CID spectrum and none are left from the HCD
spectrum. Therefore, in this example, the nal merged spectrum of the HCD and CID spectra pair is
Sm = f(60; 0:2); (130; 0:8); (217; 0:4); (433; 0:5); (346; 0:7); (493; 0:5); (199; 0:5)g, as shown on the spectrum
Sm in Figure 6.3.
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Figure 6.3: An example of the spectra merging process
6.3 Experiments and Results
In this section, the performance of the proposed method for CID and HCD spectra pairs is evaluated.
Our previously proposed de novo peptide sequencing method for HCD spectra, NovoHCD [73], and another
method for HCD and ETD spectra, pNovo+ [75] (with the option for HCD spectra), are used for comparison.
More information about NovoHCD and pNovo+ can be found in the Additional Files section. We also tried
to use UniNovo [84] in the comparison. However, instead of reporting whole peptide sequences, UniNovo
produced partial peptide sequences along with numerical values representing the mass sums of unidentied
parts. Hence, UniNovo is not included in the comparison. The reasons for choosing NovoHCD and pNovo+
are as follows. First, the proposed method focuses on the merger of the two experimental spectra, and uses a
sequencing method similar to the one in NovoHCD. The result dierence between the proposed method and
NovoHCD is expected to show the contribution of using merged spectra. Secondly, to our knowledge, there
is no more method available for CID and HCD spectra pairs other than the proposed one. Considering the
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similarity between the two types of spectra, a comparison between the proposed method and other methods
designed for HCD spectra is expected to show the improvement of using spectra pairs. Lastly, pNovo+ is used
to conduct peptide sequencing on the spectra generated by the spectra merging step in the proposed method.
A comparison of pNovo+ and proposed method in this case can show the eectiveness dierence of peptide
sequencing models in these two methods. The detailed experimental process and results are presented below.
6.3.1 Datasets
There are two pairs of CID and HCD spectral datasets used in the experiments: SCX CID decon and
SCX HCD decon, plus SCX CID no decon and SCX HCD no decon [98]. Both dataset pairs are from the
data used in [98]. MS/MS spectra were generated from a hybrid tandem mass spectrometer; they were an-
alyzed on an ETD enabled Orbitrap Velos instrument (Thermo Fisher Scientic, Bremen) connected to an
Agilent 1200 HPLC system [98]. The experimental spectra were then interpreted using Mascot software ver-
sion 2.3.02 (Matrix Science, UK). Details about the sample, instrument, and parameters used for generating
the expermental spectra can be seen in [98].
The original datasets contain various fragmentation MS/MS spectra including CID, HCD, and ETD spec-
tra. The CID and HCD spectra were chosen for the experiments here. The latter dataset pair (labelled with
\ no decon") contains spectra without deconvolution while the other pair contains spectra with deconvolu-
tion. Each spectrum comes with a precursor ion charge value and a peptide sequence indicating the peptide as
determined by Mascot. In order to conduct our experiments, spectra pairs having the same peptide sequence
were selected from the paired datasets.
When each spectrum in a spectra pair is used separately and single-spectrum-based methods output
identical and correct results, there is no need to use the proposed method for paired spectra sequencing.
Such spectra pairs are of sucient quality that any one of the two produces satisfying results. The remaining
paired spectra constitute a much more rigorous test and those were used in testing the proposed method and
comparing it with the other sequencing algorithms. We used NovoHCD as the single-spectrum-based method
to implement this selection strategy for constructing the test data set. The spectra charges and the numbers
of selected pairs of spectra in the testing datasets are summarized in Table 6.2.
Table 6.2: Number of selected spectra pairs and charges in each dataset used in the experiments
Dataset pair Charge of selected spectra Number of selected spectra
SCX CID decon
+2 to +6 403
SCX HCD decon
SCX CID no decon
+2 to +5 578
SCX HCD no decon
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Table 6.3: Parameters used in the experiments
Parameter Role in proposed method Value
1 Generation of S
0
m in spectra merging 0.01Da
2 Iteration in spectra merging 0.01Da
Thres Multiple tags used in modied NovoHCD 1600Da
Number of tags Tag integration in modied NovoHCD 10 per spectrum
Number of output sequences Candidate output 3 per spectrum
6.3.2 Parameters
There are several parameters in the proposed method, and the values used are listed in Table 6.3. All these
values are set according to our previous study and experiments [73, 100], but they can be changed by users
to suit their needs.
6.3.3 De novo peptide sequencing performance
We investigated the performance of dierent methods by comparing full length peptide sequencing accuracy.
For each spectrum (merged or experimental), a series of candidate sequences are output with ranking scores
associated with them. A higher rank indicates greater condence in the correctness of the predicted sequence.
The top three ranked candidates are considered in the performance comparison. If any one of the three
candidates interpreted from a spectrum is correct, we say that the method achieves a full length accuracy
for the given spectrum. The results for full length accuracy comparison are presented in Figures 6.4 and 6.5.
In the comparison, results from NovoHCD and the proposed method are categorized together and compared
with pNovo+. One reason for that is that the models of NovoHCD and the proposed method are similar,
so they can be categorized together and compared to pNovo+ (HCD spectra option). The other reason is
that NovoHCD is applied to each of HCD and CID spectra alone, the proposed method is applied on merged
spectra only, and pNovo+ is applied on both cases. Therefore, NovoHCD and the proposed method can be
categorized together.
From Figures 6.4 and 6.5 one can see that for both dataset pairs, the proposed method achieves higher
full length accuracy than NovoHCD when using merged spectra. Since the two methods have similar se-
quencing models, this comparison implies that the merger of the two spectra successfully provides additional
information for better peptide sequencing without introducing excessive noise or losing essential information.
The proposed method also outperforms pNovo+ where the latter uses CID or HCD spectra alone. This
proves the signicance for peptide sequencing by using paired spectra with similar dominant ions. When
pNovo+ conducted peptide sequencing on the spectra generated from the spectra merging step in the pro-
79
Figure 6.4: Full length sequencing accuracy comparison on SCX CID decon and SCX HCD decon
testing datasets.
posed method, it achieved a lower number of correctly identied peptides on both dataset pairs. This implies
an improvement of the sequencing model in the proposed method as compared to pNovo+. Finally, it is
noticeable that pNovo+ does not have a dramatic dierence on these three cases while the proposed method
along with NovoHCD does have a steady performance improvement. This may be because pNovo+ is de-
signed for HCD spectra and/or ETD spectra but not HCD and CID spectra pairs, and the model may not
work better for the merged spectra with additional information. In contrast, the proposed method, with an
extended model based on NovoHCD, is designed for merged spectra. The proposed method successfully takes
use of additional information from merged spectra and thus has better accuracy than pNovo+, even when
the latter is given the same spectra generated the merging step in the proposed method.
One key feature contributing to the success of the proposed method is the spectra merging step. This
step extracts additional signal ions from spectra pairs without introducing excessive noise, which provides a
sound foundation for the graph model built upon the merged spectra. In the algorithm of pNovo+, one ion
in a spectrum is converted into several vertices in the graph model, which could introduce additional noise.
This may eect its performance on the experimental datasets. The other key feature of the proposed method
is the model for sequencing. Multiple types of edges in the graph model represent dierent relationships
between vertices, and the AACs limit the numbers of edges and thus reduce the incidence of false positive
amino acids in the predicted candidate sequences. With the use of multiple tags, the number of possible
AACs can be restricted to an acceptable scale ( 1600Da), and the amount of calculation is reduced.
When using paired spectra for peptide sequencing, since two spectra are used, additional information for
the task can be extracted. When using the proposed method, the number of identied peptides using spectra
80
Figure 6.5: Full length sequencing accuracy comparison on SCX CID no decon and
SCX HCD no decon testing datasets.
pairs are larger than the total number of peptides identied by using CID and HCD spectra separately. One
can arrive at this conclusion by transforming the accuracies in Figures 6.4 and 6.5 into total numbers of
identied peptides given the total number of experimental spectra. This suggests that for some spectra pairs,
individual CID and HCD spectra may contain partial information for sequencing, but not enough for the
whole peptide sequence to be identied. Then, with the combination of the two, this information can be
combined, and it becomes sucient for sequencing. The spectra pairs for which NovoHCD failed to output
correct sequences when using either CID or HCD spectra alone were noted. The numbers of these spectra
pairs from the two experimental dataset pairs are shown in Table 6.4 under the heading \number of failed
pairs". The numbers of these spectra pairs successfully sequenced using the proposed method are shown in
the last column of Table 6.4. From Table 6.4 one can see that there are many spectra pairs in each dataset
pair for which neither CID nor HCD spectra alone are sucient for successful sequencing. However, correct
sequences of many of them are identied by the proposed method when using both spectra. This shows that
the proposed method for spectra pairs can ll gaps in the capabilities of single-spectrum-based methods for
de novo peptide sequencing. If a method processes the two spectra separately and combines the sequencing
results later, it may not be able to identify all of the new peptides as the proposed one does. Combining the
informative ions from both spectra makes it easy to do a successful the sequencing based on graph-theoretic
algorithms since there are sucient information in the merged spectrum.
Furthermore, we considered the relationship between the number of correctly identied peptides and
peptide length. Comparisons between the proposed method and pNovo+ on dataset pair SCX HCD no decon
and SCX ETD no decon are shown in Figures 6.6, 6.7 and 6.8. The reason for showing the results from this
pair is because it has a larger number of spectra, and so is expected to constitute a more comprehensive
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Table 6.4: Number of successful sequencing pairs from the ones for which sequencing failed by using
CID and HCD spectra alone
Dataset Number of Number of peptides successfully
pair failed pairs sequenced by proposed method
SCX CID decon
187 80
SCX HCD decon
SCX CID no decon
248 181
SCX HCD no decon
comparison.
Figures 6.6, 6.7 and 6.8 show that the proposed method outperforms pNovo+ on every peptide length in
this pair of datasets. The identication accuracy of pNovo+ drops after length 16. However, the proposed
method achieves very good results when peptide length is greater than 16, but less than 20. (Beyond 20,
the proposed method shows some decrease.) This indicates that use of multiple tags in the proposed method
contributes to the sequencing of long peptides. Our previous study on ETD and ECD spectra showed that
with the use of multiple spectra, peptide sequencing accuracy can be greatly improved on long peptides
(typically  15 amino acid long), compared to single tag usage [100]. pNovo+, however, does not include a
strategy designed specically for long peptides, and this may be a reason for the unsatisfying performance on
these peptides. The varied performance of the proposed method on very long peptides ( 20 amino acid long)
may reect the complexity of the spectra generated by these peptides. Such complexity could cause the drop
of the performance. However, since the number of the spectra generated by these very long peptides is limited
in the experimental datasets, we believe that future experiments and analysis are needed to investigate this
phenomenon.
6.4 Conclusions and future work
In this paper, a new method of de novo peptide sequencing for CID and HCD spectra pairs is proposed.
The proposed method includes a criterion for merging pairs of CID and HCD spectra and a parent mass
correction technique. The method is a modication of our previously proposed NovoHCD method. Peptide
tags and amino acid compositions are used to reduce the scale of computation in the proposed method.
Two pairs of spectral datasets were used to investigate and compare the performance of the proposed
method and two other methods designed for single spectrum (HCD or CID) data, NovoHCD and pNovo+
(HCD option). Experimental results showed that full length peptide sequencing accuracy increased dramat-
ically through the use of spectra pairs in the proposed method, with the highest accuracy of 81.31%. The
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Figure 6.6: Comparison of the number of correctly identied peptides verses peptide length for the
proposed method and pNovo+ using only CID spectra for the latter method.
proposed method has better peptide identication accuracy than either single-spectrum-based method.
In future, we will focus on improving the accuracy of the proposed method by further analyzing the
characteristics of the wrongly identied spectra, and evaluating the proposed method on more MS/MS
datasets. In addition, we are also planning to design a universal framework of de novo sequencing for all
kinds of MS/MS spectra including CID, HCD, ETD spectra and their combinations.
Acknowledgements
This work was supported by Natural Sciences and Engineering Research Council of Canada (NSERC).
Competing interests
The authors declare that they have no competing interests.
83
12 14 16 18 20 22 24 26
0
20
40
60
80
100
120
140
160
180
Number of identified spectra according to peptide length
Peptide length
N
um
be
r o
f s
pe
ct
ra
 
 
Total spectra
Proposed identified
pNovo+ identified
Figure 6.7: Comparison of the number of correctly identied peptides verses peptide length for the
proposed method and pNovo+ using only HCD spectra for the latter method.
Additional Files
This section describes the proposed method in detail including the spectra merging and parent mass correction
steps, and the how it extends NovoHCD [73].
Spectra merging
Since CID and HCD have similar dominant ions, the same fragment ions may occur in both spectra; for
example, a b3-ion observed in both experimental spectra. Therefore, in the merging step, such ions need
to be combined. In the proposed merging criterion, ions from both spectra with very small mass dierence
are rst selected. These two ions are more likely to be real fragment ions than noise since the same noise
peak is unlikely to appear in both spectra. The two ions are then transformed into one ion in the merged
spectrum with its m=z value being the average and intensity being the sum of the individual values from the
two ions, respectively. The second feature considered as a criterion in the spectra merging is complementary
ion pairs [90]. A pair of ions can be from the same spectrum or one from each spectrum; for example, a
b-ion from a CID spectrum and its complementary y-ion from a HCD spectrum. Such ions are added into
the merged spectrum. IMs and internal ions introduced previously are selected from the HCD spectrum and
also added to the merged spectrum. We denote the ions selected (or generated) from the above steps as S0m.
The mass dierence threshold used in generating S0m is denoted as 1.
Having S0m as an initial set, an iterative approach is used to select more ions to add to the merged spectra.
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Figure 6.8: Comparison of the number of correctly identied peptides verses peptide length for the
proposed method and pNovo+ using merged spectra.
Here, amino acid dierence is applied to select additional ions from CID and HCD spectra pairs. For an ion
u 2 S0m, if there is an ion v in the CID or HCD spectrum such that the m=z dierence between u and v
is close to any of the 20 amino acid masses (within a given threshold 2), v is selected. We denote all ions
selected from this step as S1m. Having S
1
m, we use the amino acid dierence to select additional ions from the
rest of the spectra pair that have one amino acid dierence to the ions in S1m, and denote the ions selected
as S2m. This step continues iteratively until no more ions can be selected using the amino acid dierence
measurement. A suitably designed threshold can be used as the stop criterion for the iteration. The last ion
set selected is denoted as Stm. One potential benet of the iteration is that we can assign weights to the ions
selected from dierent rounds of iteration. The hypothesis is that ions in the initial set S0m have the highest
condence to be real fragment ions rather than noise, and as the iteration continues, the level of condence
drops. In the current method, we did not introduce weights in order to simplify the calculation.
Another unique aspect of the proposed method is that it handles high condence ions (similar m=z, IMs,
and complimentary ions) and other ions (selected using amino acid masses) separately. The former does not
need additional selection criteria, while the latter can benet from them because of the possible false positives
introduced by comparing all 20 amino acid masses. The proposed method uses ion intensities as an additional
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selection control criterion. To be specic, if we denote the highest intensity value of the ions in the spectra
pair as Imax, ions having intensity values less than
Imax
2 are not selected. The reason behind this criterion
is that usually ions with lower intensity are more likely to be noise rather than fragment ions. An intensity
comparison (low or high) is only meaningful within one spectrum. In order to use an intensity criterion on a
pair of spectra, intensity normalization is needed. The highest intensity values in both spectrum are set to
1, and the remaining intensity values are normalized according to the ratio to the highest ones. After this
process, the two spectra have the same scale of intensity values, and the intensity criterion can be applied.
Amino acid composition information is used in a subsequent stage of the method to further reduce false
positives.
In the last step of the spectra merging process, the remaining ions in the spectra pair are examined.
The \local maximum" ions [88] are put into set St+1m in order to balance the eect of the above intensity
threshold Imax2 . A peak is called a \local maximum" if its intensity is larger than the two peaks beside
it. Researchers have found that when applying intensity information, a simple threshold is not completely
eective for dierentiating signal ions from noise ions because the ions' intensities in a spectrum tend to
be larger in the middle of the m=z range than at the two ends for CID and HCD spectra [88]. It is more
reasonable to assume that the noise ions in a narrow m=z range are equally distributed, and that signal ions
tend to be the local maxima [88]. Finally, the merged spectrum Sm =
St+1
i=0 S
i
m.
Parent mass correction
In this method, two MS/MS spectra are used and each comes with a parent peptide mass. Before the de
novo sequencing, parent mass correction is conducted. The approach introduced in [81] is used here. In
this approach, all complementary ion pairs in Sm are used, and the hypothesis is that the real parent mass
has the minimal mass dierence to complementary ion pair masses. Then by solving the following quadratic
expression (6.3), we get the optimal parent mass.
minkj=1 j (Ij + Icj )  Pmass j2
s:t: Pinf  Pmass  P sup (6.3)
In expression 6.3, Ij ; I
c
j are complementary ion pairs in Sm, k is the total number of complementary
ion pairs, and Pmass is the optimal parent mass. Pinf and P
sup are the inmum and supremum of Pmass,
respectively, which can be set as the masses of the two experimental spectra.
NovoHCD and its modication
NovoHCD [73] is a recent solution to the de novo peptide sequencing problem for HCD spectra. It is based
on multi-edge graphs with integration of amino acid composition (AAC) and peptide tags.
NovoHCD rst uses peptide tags to separate a whole peptide sequence into three parts: prex, tag, and
sux. Several tags are used for one spectrum and each tag is used separately. For each tag, NovoHCD
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builds a multi-edge graph model on the prex and sux separately to nd partial peptide sequences, and
AAC information is used to limit the number of edges in the graph. NovoHCD nally combines the three
parts, each possible prex and sux sequences and the tags, to generate a candidate peptide. All possible
candidates based on dierent tags are ranked through a ranking scheme and output.
A multi-edge graph G includes ve dierent types of edges reecting the relationships of complementary
ions, amino acid dierence between ions, and loss of small molecules of ions. Detailed denition of edges can
be seen in [73]. Having graph G, another kind of graph, induced by all vertices in G from a single cleavage
site of the peptide, can be constructed. This is named as a \basic structure" of G at a cleavage site. Then,
by nding adjacent basic structures, continuous amino acids can be inferred. The detailed steps of inferring
basic structure (and amino acids) can be seen in [73].
pNovo and its comparison with NovoHCD
pNovo [72], an alternative software designed for HCD spectra, is used for performance comparison with
NovoHCD in our previous study [73]. pNovo applies a graph-theoretic approach for sequencing. It rst
converts each ion in a spectrum into several vertices representing dierent types of ions and merges vertices
with similar masses, and then connects two vertices if their mass dierence is close to one of the 20 amino
acid masses. After that, it assigns weights to edges and generates best score paths from the graph model
using a scoring function designed by the authors.
Dierences between NovoHCD and pNovo are in the graph model and scoring scheme. pNovo converts
ions from an experimental spectrum into several vertices, which could introduce additional noise into the
graph since one noisy ion is converted into several noisy vertices in the graph. With additional noisy vertices,
false positive edges can be added into the graph when comparing mass dierence between two ions. This
could make the path nding very dicult and result in output of incorrect paths. In contrast, NovoHCD uses
multiple types of edges to represent dierent types of relationships between two ions, and no added vertex
is introduced. When forming edges of the graph in NovoHCD, AAC is used to reduce false positive edges.
The scoring scheme in pNovo includes a weight assignment and path scoring function, while NovoHCD uses
a ranking-based scoring scheme for peptide candidates. Experimental results on several HCD datasets show
that NovoHCD outperforms pNovo [72] in terms of full length sequencing accuracy.
NovoHCD must be modied for use in the proposed method. The major modications are to the peptide
tag strategy and the candidate ranking scheme. In NovoHCD, a single tag is used for HCD spectra to separate
whole sequences into three parts. Upon further study, we found that this strategy is not eective for long
peptides (typically over 15 amino acid long). Therefore, multiple tags are used, as in [17], to separate the
whole sequences, and a predened threshold (set to be 1600 Da for the proposed method) is used to control
if further separation is needed.
For the ranking scheme, NovoHCD considers parent peptide mass Pmass and the number of IMs in a
HCD spectrum. The magnitude of mass dierence between a peptide candidate sequence Pcan and Pmass is
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denoted as mP . In the proposed method, internal ions in the merged spectrum are also included. Internal
ions in the form of b- and y- ions with length of up to two amino acids are considered. Given Pcan, we list
all internal ions from it and compare them to the merged spectrum. The number of matched internal ions
and the number of IMs are added, and denoted as AA. For a given pair of spectra, the ranking score of Pcan
can be represented as a vector CP (AA;mP ). The ranking approach rst sorts CP according to its initial
element AA in decreasing order, and then arranges mP in increasing order as a secondary key. After this
process, all candidates are ranked. In the proposed method, for a pair of input spectra, the top 3 ranked
candidates are output.
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Chapter 7
Summary and Future Work
7.1 Summary
Peptide sequencing from MS/MS has become an important topic in proteomics. It provides essential infor-
mation for protein structure and function study. With the development of MS/MS ionization techniques
and various MS/MS spectra generated from them, suitable computational methods are needed for the data
interpretation. Currently, de novo peptide sequencing methods have drawn a lot of attention because of their
unique advantages compared to database searching. Many algorithms for de novo peptide sequencing have
been developed with application to dierent types of MS/MS spectra. The main limitations of current de
novo peptide sequencing methods are the lack of suitable models reecting MS/MS spectra, limited infor-
mation extracted from the spectra, and inecient use of multiple spectra. This thesis aims to address some
of the limitations in current peptide sequencing methods with the four objectives listed in Chapter 1. The
work presented in Chapters 2 to 6 of the thesis has achieved these objectives.
Chapter 2 presents a comprehensive review of de novo peptide sequencing methods and achieves Objective
1. It summarizes recent developments of computational methods for various types of typical experimental
data, compares and analyzes their advantages and disadvantages, points out the limitations of current studies,
and identies directions for improvements and new method design.
In Chapter 3, a new model containing useful information from the MS/MS spectra is developed for de
novo peptide sequencing. It modies the traditional spectrum graph model to be a graph with multiple types
of edges and integrated amino acid combination (AAC) information and peptide tags. This method is then
evaluated on HCD spectra and compared with another competing method on several experimental datasets.
Results show that it outperforms other methods over the ve datasets.
Based on the success of the method proposed in Chapter 3, other types of MS/MS spectra, ECD and ETD
spectra, to be specic, are studied in Chapter 4. A de novo sequencing method named NovoExD designed
for ECD and ETD spectra is presented in this chapter. NovoExD modies the previous model in Chapter 3
and considers multiple peptide tags and fragment ion charge information. Experiments conducted on three
dierent datasets show that NovoExD outperforms another similar method. Objectives 2 and 3 have been
achieved by the methods developed in Chapters 2 and 3.
Objective 4 is about methods for multiple spectra. Chapter 5 presents a framework for multiple spectra
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sequencing with new features and models. It is applied to paired CID (or HCD) and ECD (or ETD) spectra.
These spectra pairs have dierent dominant fragment ions and are complementary to each other. There are
already some other methods for these spectra pairs, and results on several experimental datasets show that
the proposed method outperforms similar methods available.
Chapter 6 presents a de novo peptide sequencing method for CID and HCD spectra pairs. These spectra
pairs have similar dominant ions but are accompanied by other ion types with dierent properties. Less
attention has been paid in the literature to these spectra pairs. Experimental results show that the proposed
method works well on several testing datasets, and identies some new peptides that other single-spectrum-
based methods cannot identify. Objective 4 is accomplished by these two chapters. Therefore, all objectives
proposed for the thesis have been achieved.
To sum up, the following works have been completed in this thesis:
 Reviewed de novo peptide sequencing methods, analyzed their advantages and disadvantages, and found
limitations and potential improvement directions.
 Based on the literature review, proposed a new graph model for de novo peptide sequencing and applied
it to HCD spectra.
 Revised the proposed method for HCD spectra, and developed a new de novo peptide sequencing
method for ECD and ETD spectra by considering their unique features.
 Developed a framework for de novo peptide sequencing of multiple spectra and applied it to paired
CID (or HCD) and ECD (or ETD) spectra.
 Proposed a new de novo peptide sequencing method for CID and HCD spectra pairs including a
specically designed spectra merging criteria and modication of a previously proposed method for
paired spectra sequencing.
7.2 Contributions
The thesis provides a series of novel computational de novo peptide sequencing methods for dierent types of
MS/MS spectra. All proposed methods have been evaluated on several experimental datasets and compared
with other methods. In the following, specic contributions are listed:
 A comprehensive literature review of de novo peptide sequencing methods of MS/MS spectra is given.
It summarizes the development of the methods, analyzes the advantages and disadvantages of dierent
methods, and provides guidelines for lling gaps between current methods and developing advanced
methods as further study.
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 An improved graph model for de novo peptide sequencing is proposed with multiple types of edges
reecting dierent relationships between ions in an MS/MS spectrum. It is applied to a new type of
MS/MS spectra, HCD spectra, for peptide sequencing.
 A new de novo peptide sequencing method is proposed with multiple peptide tags and amino acid
composition information included to reduce the complexity and increase accuracy of the method. It is
applied to ECD and ETD spectra with the consideration of their unique features.
 A framework for de novo peptide sequencing of multiple spectra is developed with application to paired
CID (or HCD) and ECD (or ETD) spectra. The framework provides general guidelines for the de novo
peptide sequencing of multiple spectra, and is potentially applicable to various spectra combinations
with suitable modication.
 A new de novo peptide sequencing method for CID and HCD spectra pairs is developed. It includes a
specically designed spectra merging criteria and modies a previously proposed method to suit CID
and HCD spectra pairs.
7.3 Future Work
Based on the work presented in the thesis of de novo peptide sequencing, the following directions for future
research work are proposed.
 De novo peptide sequencing methods for spectra with post-translational modications (PTMs).
One major advantage of de novo peptide sequencing is its independence of a protein database. Thus
it has the ability to identify peptides with PTMs. Among all kinds of spectra, ECD and ETD spectra
are the most suitable for identifying peptides with PTMs because of the unique features of these
spectra. A computational method for ECD and ETD spectra without consideration of PTMs has been
presented in this thesis (NovoExD). With suitable modication, it can be extended to the case with
PTMs. A practical way to start is to consider one common PTM, and make adjustment of the amino
acid masses used in the method. After that, more PTMs could be considered. One recent study has
claimed that only a limited number of PTMs can occur in a peptide although the types of PTMs can
be numerous [106]. Therefore, researchers should consider limiting the number of PTMs per spectrum
in the designed method.
 New methods for multiple spectra de novo peptide sequencing.
Multiple spectra sequencing continues to increase in popularity with the availability of various kinds of
MS/MS spectra. Two computational methods have been presented in the thesis for dierent pairs of
spectra. However, there is still room for new for multiple spectra sequencing methods for other spectra
combinations; for example, CID, HCD, and ETD.
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 Preprocessing methods for multiple spectra de novo peptide sequencing.
There are already a lot of preprocessing methods developed for traditionally used CID spectra, but
not many for multiple spectra sequencing techniques. One key preprocessing step in these techniques
is spectra merging. New methods can focus on the improvement of merging criteria for the pairs of
spectra studied in this thesis, or the merging of other kinds of spectra combinations. In addition,
eective denoising methods for these spectra can be another potential research topic.
 Software development for the proposed de novo peptide sequencing methods.
A series of computational methods are presented in this thesis, and it would be helpful to develop
integrated software packages for interested users. All presented methods can be integrated into one
single software package to be applicable for peptide sequencing of dierent types of spectra or spectra
combinations.
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